[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1175
1. Gundy S, Székely G, Farkas G, Pulay A, Remenár E: [Problems occurring in the application of cytogenetic biomarkers for alcoholics with and without malignant diseases]. Magy Onkol; 2008 Jun;52(2):153-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To clarify these problems, 432 head and neck cancer patients (HNCP), 62 alcoholics with alcoholic hepatitis (ALCL), and 101 disease-free chronic alcoholics (ALC) were examined.
  • Despite clinically confirmed alcohol-related diagnoses (and GGT and MCV values) only about half of HNCPs and ALCLs reported about any alcohol consumption, in contrast to the realistic self-reports of ALCs.
  • In cytogenetic case control investigations no difference between the spontaneous rate of chromosomal aberrations (CAs) of healthy controls and ALCs was found, however, genetic instability expressed as a 40-50% elevation rate of CAs in HNCPs and ALCLs might be associated with systemic inflammatory reaction of lymphocytes.
  • Bleomycin sensitivity assay showed the highest break/cell (b/c) values not in HNCPs (1.06 b/c) as it was reported earlier, but in "healthy" ALCs (1.52 b/c).

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18640891.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor
  •  go-up   go-down


2. Shen M, Huang W, Zhang W, Hao X, Sun WH, Redshaw C: Synthesis and characterisation of alkylaluminium benzimidazolates and their use in the ring-opening polymerisation of ε-caprolactone. Dalton Trans; 2010 Nov 7;39(41):9912-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment of L1 with one or two equivalents of Et(2)AlCl led to the adducts EtAl(L1)(2)·AlEtCl(2) (7) or Et(2)AlL1·AlEtCl(2) (8), respectively.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20842299.001).
  • [ISSN] 1477-9234
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


3. Sun XW, Sun GL, Xiao LJ: [Evaluation of gingival inflammation related to different retraction agents]. Hua Xi Kou Qiang Yi Xue Za Zhi; 2008 Feb;26(1):53-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The quantity of gingival crevicular fluid (GCF) and the active level of aspartate amino-transferase (AST) in gingival crevicular fluid were measured before and 1, 3, 5, 7, 9 days after retracting gingiva by four kinds retraction agents.
  • RESULTS: The change of the GCF from the smallest to the largest was sodium chloride, 0.1% HCl-epinephrine, 25% AlCl,, 15.5% Fe2 (SO)3.
  • CONCLUSION: 0.1% HCl-epinephrine is suggested in patient without cardiovascular disease.
  • For patient with cardiovascular disease, the better substitute is 25% AlCl3.

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. EPINEPHRINE .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18357884.001).
  • [ISSN] 1000-1182
  • [Journal-full-title] Hua xi kou qiang yi xue za zhi = Huaxi kouqiang yixue zazhi = West China journal of stomatology
  • [ISO-abbreviation] Hua Xi Kou Qiang Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Chlorides; 3CYT62D3GA / aluminum chloride; YKH834O4BH / Epinephrine
  •  go-up   go-down


Advertisement
4. Rodis DG, Liatsos GD, Moulakakis A, Pirounaki M, Tasidou A: Paraneoplastic cerebellar degeneration: initial presentation in a patient with anaplastic T-cell lymphoma, associated with ichthyosiform cutaneous lesions. Leuk Lymphoma; 2009 Aug;50(8):1369-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic cerebellar degeneration: initial presentation in a patient with anaplastic T-cell lymphoma, associated with ichthyosiform cutaneous lesions.
  • [MeSH-major] Ichthyosis / etiology. Lymphoma, Primary Cutaneous Anaplastic Large Cell / diagnosis. Paraneoplastic Cerebellar Degeneration / diagnosis. Paraneoplastic Syndromes / etiology. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Diseases, Metabolic / diagnosis. Cerebellar Ataxia / etiology. Cyclophosphamide / administration & dosage. Diagnostic Errors. Doxorubicin / administration & dosage. Dysarthria / etiology. Fatal Outcome. Fever / etiology. Humans. Lymph Nodes / pathology. Male. Mental Disorders / diagnosis. Prednisolone / administration & dosage. Vincristine / administration & dosage


5. Reiter A: Diagnosis and treatment of childhood non-hodgkin lymphoma. Hematology Am Soc Hematol Educ Program; 2007;:285-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and treatment of childhood non-hodgkin lymphoma.
  • Major advances have been made in the treatment of childhood non-Hodgkin lymphoma (NHL).
  • Currently established therapy groups are lymphoblastic lymphoma (LBL) of precursor B- or T-cell type, mature B-cell neoplasms (B-NHL), and anaplastic large cell lymphoma (ALCL).
  • In patients with ALCL, comparable results are achieved with either strategy, although this group has the highest relapse rate.


6. Li D, Li GD, Liu WP, Zhang WY, Li FY, Liao DY: [Prognostic analysis of 51 cases of primary nodal diffuse large B-cell lymphomas]. Zhonghua Xue Ye Xue Za Zhi; 2005 Apr;26(4):223-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic analysis of 51 cases of primary nodal diffuse large B-cell lymphomas].
  • OBJECTIVE: To explore the prognostic factors of primary nodal diffuse large B-cell lymphomas (N-DLBCL).
  • Antibodies used for study were anti-CD20, CD79alpha, CD45RO, CD3, Bcl-2, Ki-67, CD30, CD15, kappa, lambda, Cyclin D1, TdT, GFAP, CK, MPO.
  • RESULTS: Of the 51 cases of N-DLBCLs, 40 were reclassified as centroblastic, 3 B-immunoblastic, 1 T-cell/histiocytes rich, 2 B-cell anaplastic large cell, 1 plasmablastic, and 4 unclassified.
  • The median Ki-67 index was 50.0% and the index more than 40% was found in 35 cases (68.6%).
  • The 5-year OS rates patients with International Prognosis Index (IPI) >/= 3 was lower than that with IPI < 3 (P < 0.01).
  • The 5-year OS rates for patients with Ki-67 index more than 40% was lower than that with less than 40% (P < 0.05).
  • CONCLUSION: IPI, B symptoms and Ki-67 index are the prognostic factors for patients with N-DLBCL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / metabolism. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD15 / analysis. Antigens, CD20 / analysis. Antigens, CD30 / analysis. Antigens, CD45 / analysis. Child. Child, Preschool. Cyclin D1 / analysis. Female. Follow-Up Studies. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Middle Aged. Prognosis. Survival Analysis. Young Adult

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15949265.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD20; 0 / Antigens, CD30; 0 / Ki-67 Antigen; 136601-57-5 / Cyclin D1; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


7. Cluzeau T, Pécuchet N, Mounier N, Vignot S: [Implications of ALK (anaplastic lymphoma kinase) in oncohematology]. Bull Cancer; 2010 Aug;97(8):991-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Implications of ALK (anaplastic lymphoma kinase) in oncohematology].
  • [Transliterated title] Implications d'ALK (anaplastic lymphoma kinase) en oncohématologie.
  • The anaplastic lymphoma kinase gene (ALK) code for a receptor tyrosine-kinase.
  • The fusion proteins from the ALK gene have been identified in oncohaematology malignancies including ALK positive anaplastic lymphoma large cell and non small cells lung cancer with EML4-ALK fusion gene.
  • Constitutive activation generated by modification of this protein leads activation of anti apoptotic and survey pathways that makes it a prime target for these 2 subtypes of disease.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Lymphoma, Large-Cell, Anaplastic / enzymology. Neoplasm Proteins / genetics. Oncogene Proteins, Fusion / genetics. Protein-Tyrosine Kinases / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20483705.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Neoplasm Proteins; 0 / Nucleoplasmins; 0 / Oncogene Proteins, Fusion; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 27
  •  go-up   go-down


8. Brugières L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, Mann G, Zsiros J, Uyttebroeck A, Marky I, Lamant L, Reiter A: Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol; 2009 Feb 20;27(6):897-903
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group.
  • PURPOSE: To compare the efficacy and safety of two methotrexate doses and administration schedules in children with anaplastic large-cell lymphoma (ALCL).
  • PATIENTS AND METHODS: This randomized trial for children with ALCL was based on the Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Muenster 90 (NHL-BFM90) study protocol and compared six courses of methotrexate 1 g/m2 over 24 hours and an intrathecal injection (IT) followed by folinic acid rescue at 42 hours (MTX1 arm) with six courses of methotrexate 3 g/m2 over 3 hours followed by folinic acid rescue at 24 hours without IT (MTX3 arm).
  • This trial involved most European pediatric/lymphoma study groups and a Japanese group.
  • RESULTS: Overall, 352 patients (96% ALK positive) were recruited between 1999 and 2005; 175 were randomly assigned to the MTX1 arm, and 177 were assigned to the MTX3 arm.
  • CONCLUSION: The results of the NHL-BFM90 study were reproduced in this large international trial.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Lymphoma, Large B-Cell, Diffuse / drug therapy. Methotrexate / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19139435.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


9. Kesler MV, Paranjape GS, Asplund SL, McKenna RW, Jamal S, Kroft SH: Anaplastic large cell lymphoma: a flow cytometric analysis of 29 cases. Am J Clin Pathol; 2007 Aug;128(2):314-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma: a flow cytometric analysis of 29 cases.
  • We report our experience with flow cytometric (FC) analysis of 29 cases of anaplastic large cell lymphoma (ALCL).
  • Morphologic analysis of processed cytocentrifuged preparations demonstrated neoplastic cells in 28 cases.
  • Of 21 cases, 13 were anaplastic lymphoma kinase (ALK)+, all of which were CD4+, vs 5 of 8 ALK - cases (P = .042).
  • Most ALCLs can be detected and characterized by multiparameter FC analysis.
  • [MeSH-major] Antigens, CD / analysis. Flow Cytometry / methods. Lymphoma, Large B-Cell, Diffuse / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD30 / analysis. Antigens, CD45 / analysis. Child. Child, Preschool. Female. Humans. Light. Male. Middle Aged. Protein-Tyrosine Kinases / analysis. Receptor Protein-Tyrosine Kinases. Scattering, Radiation

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17638668.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


10. Matsumoto H, Koga H, Honda K, Sadahira Y, Suetugu Y, Mikami M, Nakanishi H, Yata K, Wada H, Sugihara T, Haruma K: Characterization of secondary GI lesions with anaplastic large-cell (Ki-1) lymphoma: a first report of two cases. Gastrointest Endosc; 2005 Apr;61(4):607-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of secondary GI lesions with anaplastic large-cell (Ki-1) lymphoma: a first report of two cases.
  • [MeSH-major] Gastrointestinal Neoplasms / enzymology. Gastrointestinal Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / enzymology. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812421.001).
  • [ISSN] 0016-5107
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VAP-cyclo protocol
  •  go-up   go-down


11. Alalade AO, Odejinmi FO: A rare and potentially fatal cause of pelvic pain in pregnancy: anaplastic large cell lymphoma. J Obstet Gynaecol; 2006 Oct;26(7):691-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare and potentially fatal cause of pelvic pain in pregnancy: anaplastic large cell lymphoma.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Pelvic Pain / etiology. Pregnancy Complications, Neoplastic / pathology


12. Grewal JS, Smith LB, Winegarden JD 3rd, Krauss JC, Tworek JA, Schnitzer B: Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature. Ann Hematol; 2007 Jul;86(7):499-508
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement: a report of three cases and a review of the literature.
  • Anaplastic large cell lymphoma (ALCL) is an aggressive neoplasm of T- or null cell phenotype and is recognized as a distinct clinicopathologic subtype of non-Hodgkin lymphoma (NHL) in the revised World Health Organization (WHO) classification of hematopoietic neoplasms.
  • Most cases with leukemic involvement are the small cell variant of ALCL.
  • These cases often lack the pleomorphism seen in the common variant of ALCL and may be misdiagnosed.
  • We report a series of three patients who presented with leukemic phase ALCL.
  • The patients included an 11-year-old boy, a 29-year-old man, and a 59-year-old woman.
  • The patients in our case series with leukemic phase ALCL exhibited rare clinical features.
  • The patients presented with massive extranodal disease involving cerebrospinal fluid (CSF), liver, spleen, lungs, and bone marrow.
  • Two of the patients had small cell variant and the third patient had common type ALCL.
  • The neoplastic cells in all three patients were ALK positive; however these patients died within months of diagnosis.
  • Leukemic phase ALCL is rare, and behaves in an aggressive manner.
  • Some, but not all, cases in the literature presenting with peripheral blood involvement had small cell variant ALCL, as seen in two of our cases.
  • The leukemic phase of ALCL should be considered when a T-cell leukemia with unusual morphologic features is encountered.
  • [MeSH-major] Leukemia / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17396261.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 91
  •  go-up   go-down


13. Jarzembowski JA: Anaplastic large cell lymphoma: looks can be deceiving. Pediatr Dev Pathol; 2007 May-Jun;10(3):169-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma: looks can be deceiving.
  • [MeSH-major] Biomarkers, Tumor / immunology. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / immunology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Pediatr Dev Pathol. 2007 May-Jun;10(3):181-91 [17535098.001]
  • (PMID = 17535094.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Comment; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Loddenkemper C, Longerich T, Hummel M, Ernestus K, Anagnostopoulos I, Dienes HP, Schirmacher P, Stein H: Frequency and diagnostic patterns of lymphomas in liver biopsies with respect to the WHO classification. Virchows Arch; 2007 May;450(5):493-502
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency and diagnostic patterns of lymphomas in liver biopsies with respect to the WHO classification.
  • However, the applicability of this classification to a representative number of hepatic lymphomas in liver biopsy specimens has not yet been investigated.
  • The frequency and infiltration pattern of a series of 205 liver biopsies with lymphoma manifestations was analyzed with the aid of immunohistochemical and molecular pathological analyses.
  • Diffuse large B-cell lymphoma (DLBCL) was by far the most frequent entity, comprising 45% of the cases analyzed.
  • Using a previously published immunohistochemical algorithm, 35% of 80 DLBCL were assigned to a germinal center B-cell-like (GCB) and 65% to a non-GCB group.
  • Most B-cell lymphoma entities involving the liver revealed a characteristic infiltration pattern.
  • Diagnostically challenging entities were T-cell-rich B-cell lymphomas, anaplastic large cell lymphomas and peripheral T-cell lymphomas, which frequently required additional molecular clonality assessment.
  • Overall, the percentage of T-cell lymphomas in the liver (12%) was higher as compared to other extranodal sites except for the skin and the small intestine.
  • This study provides relevant data on the distribution of hepatic lymphomas and demonstrates the applicability of the WHO classification proposing a diagnostic algorithm for liver biopsies.
  • [MeSH-major] Liver Neoplasms / pathology. Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1996 Nov 1;78(9):2011-9 [8909324.001]
  • [Cites] Dig Dis Sci. 1997 Nov;42(11):2241-5 [9398801.001]
  • [Cites] Am J Clin Pathol. 1998 May;109(5):600-9 [9576580.001]
  • [Cites] Mod Pathol. 1998 Apr;11(4):404-10 [9578094.001]
  • [Cites] J Med Invest. 1998 Feb;44(3-4):215-7 [9597812.001]
  • [Cites] Am J Gastroenterol. 1998 Nov;93(11):2301-2 [9820427.001]
  • [Cites] Pathol Res Pract. 1998;194(11):781-9 [9842637.001]
  • [Cites] Leuk Lymphoma. 1998 Nov;31(5-6):463-76 [9922037.001]
  • [Cites] Ann Diagn Pathol. 1998 Dec;2(6):363-9 [9930573.001]
  • [Cites] J Pathol. 1999 Jun;188(2):146-54 [10398157.001]
  • [Cites] Am J Surg Pathol. 1999 Sep;23(9):1124-30 [10478674.001]
  • [Cites] Eur J Haematol. 2005 Jun;74(6):453-65 [15876249.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Am J Clin Pathol. 2000 Oct;114(4):523-33 [11026098.001]
  • [Cites] Blood. 2002 Feb 1;99(3):815-21 [11806981.001]
  • [Cites] Crit Rev Immunol. 2002;22(1):47-103 [12186188.001]
  • [Cites] Hepatology. 2003 Apr;37(4):781-7 [12668970.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):903-11 [12826882.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Cancer. 1974 Mar;33(3):657-74 [4592903.001]
  • [Cites] Am J Clin Pathol. 1981 Jun;75(6):816-21 [6167159.001]
  • [Cites] Am J Pathol. 1983 Nov;113(2):165-71 [6605688.001]
  • [Cites] J Histochem Cytochem. 1984 Feb;32(2):219-29 [6198355.001]
  • [Cites] Arch Pathol Lab Med. 1986 Jun;110(6):553-5 [3010899.001]
  • [Cites] Semin Liver Dis. 1987 Aug;7(3):257-68 [3317862.001]
  • [Cites] Gastroenterol Clin Biol. 1989 Apr;13(4):343-52 [2661293.001]
  • [Cites] Histopathology. 1993 Sep;23(3):217-24 [8225239.001]
  • [Cites] Histopathology. 1995 Apr;26(4):311-21 [7607619.001]
  • [Cites] Cancer. 1993 Apr 15;71(8):2639-46 [8453587.001]
  • (PMID = 17431676.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1888718
  •  go-up   go-down


15. Liang Q, Ye ZY, Su ZL, Lin HL, Shao CK, Lin SX, Rao HL, Mei KY, Zhao T, Liu YH, Luo DL, Zhu MG, Chen SH, Lin TY: [Clinicopathologic study of 963 cases of mature T-cell and natural killer/T-cell lymphoma with respect to 2008 WHO classification of lymphoid neoplasms]. Zhonghua Bing Li Xue Za Zhi; 2010 May;39(5):291-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of 963 cases of mature T-cell and natural killer/T-cell lymphoma with respect to 2008 WHO classification of lymphoid neoplasms].
  • OBJECTIVE: To study the clinicopathologic features of various types of mature T-cell and natural killer (NK)/T-cell lymphoma in Guangdong, China, with respect to the 2008 WHO classification of lymphoid neoplasms.
  • METHODS: Eleven hundred and thirty-seven (1137) cases of mature T-cell or NK/T-cell lymphoma diagnosed during the period from 2002 to 2006 in Guangzhou area were retrieved.
  • RESULTS: Nine hundred and sixty-three (963) cases fulfilled the diagnostic criteria of mature T-cell or NK/T-cell lymphoma and accounted for 20.1% of all cases of lymphoma encountered during the same period (963/4801).
  • A predominance of extranodal involvement was noted in 644 cases (66.9%), while 319 cases (33.1%) showed mainly nodal disease.
  • The prevalence of various lymphoma subtypes was as follows: peripheral T-cell lymphoma, unspecified (PTCL, NOS) 293 cases (30.4%), extranodal NK/T-cell lymphoma, nasal type 281 cases (29.2%), anaplastic large cell lymphoma (ALCL) 198 cases (20.6%), and angioimmunoblastic T-cell lymphoma (AILT) 46 cases (4.8%).
  • The median age of the patients was 44 years, with the peak age of PTCL, NOS, extranodal NK/T-cell lymphoma, nasal type and AILT being 55 to 64 years, 25 to 54 years and 65 to 74 years, respectively.
  • ALK-positive ALCL occurred more frequently in young age, while the ALK-negative ALCL cases occurred mainly in the elderly.
  • CONCLUSIONS: Extranodal lesions predominate in mature T-cell and NK/T-cell lymphomas occurring in Guangzhou area.
  • The most common subtype was PTCL, NOS, followed by extranodal NK/T-cell lymphoma, nasal type, ALCL and AILT.
  • The relatively frequent occurrence of extranodal NK/T-cell lymphoma, nasal type in Guangdong area is likely associated with the high incidence of Epstein-Barr virus infection there.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell, Peripheral / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20654150.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


16. Do V, Shifrin DA, Oostendorp L: Lymphoma of the breast capsule in a silicone implant-reconstructed patient. Am Surg; 2010 Sep;76(9):1030-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoma of the breast capsule in a silicone implant-reconstructed patient.
  • [MeSH-major] Adenocarcinoma / surgery. Breast Implantation. Breast Implants. Breast Neoplasms / surgery. Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasms, Second Primary / surgery

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20836362.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


17. Roldán-Valadez E, Ortega-López N, Cervera-Ceballos E, Valdivieso-Cárdenas G, Vega-González I, Granados-García M: Whole-body (18)F-FDG PET/CT in primary non-Hodgkin's lymphoma of the thyroid associated with Hashimoto's thyroiditis and bilateral kidney infiltration. Rev Esp Med Nucl; 2008 Jan-Feb;27(1):34-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-body (18)F-FDG PET/CT in primary non-Hodgkin's lymphoma of the thyroid associated with Hashimoto's thyroiditis and bilateral kidney infiltration.
  • Ultrasound and a thyroid gammagram showed an image consistent with multinodular goiter with a hyperfunctioning nodule in the right lobe.
  • Due to the history of Hashimoto's thyroiditis and a rapid increase in size of the thyroid gland, diagnoses of thyroid lymphoma and anaplastic thyroid cancer were considered.
  • Fine needle aspiration was insufficient for diagnosis, and the product of thyroidectomy confirmed the diagnosis of diffuse large B-cell lymphoma.
  • Chemotherapy using cyclophosphamide, vincristine and dexamethasone (COP modified) led to a dramatic response of the tumor and a complete resolution of compressive symptoms.
  • [MeSH-major] Diagnostic Errors. Hashimoto Disease / radionuclide imaging. Kidney / pathology. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Positron-Emission Tomography. Thyroid Neoplasms / radionuclide imaging. Tomography, X-Ray Computed. Whole Body Imaging
  • [MeSH-minor] Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Female. Fluorodeoxyglucose F18. Goiter, Nodular / diagnosis. Humans. Radiopharmaceuticals. Remission Induction. Thyroidectomy. Thyroxine / therapeutic use. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18208780.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q51BO43MG4 / Thyroxine
  •  go-up   go-down


18. Chen KT: Rhabdomyosarcoma in an adult presenting with nodal metastasis: a pitfall in fine-needle aspiration cytology of lymph nodes. Diagn Cytopathol; 2005 May;32(5):303-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The correct diagnosis of metastatic RMS became apparent when the primary sinonasal tumor, detected in a CT, was biopsy proven to be an alveolar RMS.
  • Retrospectively, there were helpful clues to the correct diagnosis in the nodal FNA and biopsy.
  • When FNA cytology or biopsy histology of a lymph node suggests metastatic carcinoma but the tumor cells are nonimmunoreactive to carcinoma markers, the differential diagnosis should be expanded to include not only metastatic melanoma but also metastatic sarcoma and lymphoma.
  • Cytologically, the presence of multinucleated giant tumor cells, including the rosette forms, in the FNA smears should alert the cytopathologist to the possibilities of sarcoma and anaplastic large cell lymphoma.
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Etoposide / administration & dosage. Fatal Outcome. Female. Humans. Ifosfamide / administration & dosage. Lymphatic Metastasis. Radiotherapy. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15830359.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 6PLQ3CP4P3 / Etoposide; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


19. Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project: International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol; 2008 Sep 1;26(25):4124-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes.
  • PURPOSE: Peripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTCL) are rare and heterogeneous forms of non-Hodgkin's lymphoma (NHL) that, in general, are associated with a poor clinical outcome.
  • RESULTS: A diagnosis of PTCL or NKTCL was confirmed in 1,153 (87.8%) of the cases.
  • The most common subtypes were PTCL not otherwise specified (NOS; 25.9%), angioimmunoblastic type (18.5%), NKTCL (10.4%), and adult T-cell leukemia/lymphoma (ATLL; 9.6%).
  • Misclassification occurred in 10.4% of the cases including Hodgkin's lymphoma (3%), B-cell lymphoma (1.4%), unclassifiable lymphoma (2.8%), or a diagnosis other than lymphoma (2.3%).
  • The use of an anthracycline-containing regimen was not associated with an improved outcome in PTCL-NOS or angioimmunoblastic type, but was associated with an improved outcome in anaplastic large-cell lymphoma, ALK positive.
  • However, expert hematopathology review is important for accurate diagnosis.
  • The clinical outcome for patients with most of these lymphoma subtypes is poor with standard therapies, and novel agents and new modalities are needed to improve survival.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / mortality. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18626005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Investigator] Savage K; Connors J; Gascoyne R; Chhanabhai M; Wilson W; Jaffe E; Armitage J; Vose J; Weisenburger D; Anderson J; Ullrich F; Bast M; Hochberg E; Harris N; Levine A; Nathwani B; Miller T; Rimsza L; Montserrat E; Lopez-Guillermo A; Campo E; Cuadros M; Alvarez Ferreira J; Martinez Delgado B; Holte H; Delabie J; Rüdiger T; Müller-Hermelink K; Reimer P; Adam P; Wilhelm M; Schmitz N; Nerl C; Lister A; Norton A; MacLennan KA; Luigi Zinzani P; Pileri S; Federico M; Bellei M; Coiffier B; Berger F; Tanin I; Wannakrairot P; Au W; Liang R; Loong F; Rajan S; Sng I; Tobinai K; Matsuno Y; Morishima Y; Nakamura S; Seto M; Tanimoto M; Yoshino T; Suzumiya J; Ohshima K; Kim WS; Ko YH
  •  go-up   go-down


20. Oyarzo MP, Medeiros LJ, Atwell C, Feretzaki M, Leventaki V, Drakos E, Amin HM, Rassidakis GZ: c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma. Blood; 2006 Mar 15;107(6):2544-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] c-FLIP confers resistance to FAS-mediated apoptosis in anaplastic large-cell lymphoma.
  • We hypothesized that inhibition of the FAS-mediated apoptosis pathway by FLICE-like inhibitory protein (c-FLIP) may contribute to oncogenesis in ALK+ anaplastic large-cell lymphoma (ALCL).
  • Treatment with increasing concentrations of CH-11 (CD95/FAS agonistic antibody) had no effect on cell viability of 2 ALK+ ALCL cell lines, Karpas 299 and SU-DHL1, each expressing high levels of c-FLIP.
  • However, inhibition of endogenous c-FLIP expression by specific c-FLIP siRNA in Karpas 299 and SU-DHL1 cells treated with CH-11 resulted in FAS-mediated cell death associated with increased annexin V binding, apoptotic morphology, and cleavage of caspase-8.
  • In 26 ALK+ ALCL tumors, assessed for expression of DISC-associated proteins, CD95/FAS and c-FLIP were commonly expressed, in 23 (92%) of 25 and 21 (91%) of 23 tumors, respectively.
  • By contrast, CD95L/FASL was expressed in only 3 (12%) of 26 ALCL tumors, although it was strongly expressed by surrounding small reactive lymphocytes.
  • Our findings suggest that overexpression of c-FLIP protects ALK+ ALCL cells from death-receptor-induced apoptosis and may contribute to ALCL pathogenesis.
  • [MeSH-major] Antigens, CD95 / physiology. Apoptosis. Intracellular Signaling Peptides and Proteins / physiology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Annexin A5 / metabolism. CASP8 and FADD-Like Apoptosis Regulating Protein. Caspase 8. Caspases / metabolism. Cell Line, Tumor. Gene Expression Regulation, Neoplastic. Humans. RNA, Small Interfering / pharmacology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304056.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexin A5; 0 / Antigens, CD95; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; 0 / CFLAR protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / RNA, Small Interfering; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspases
  •  go-up   go-down


21. Sandlund JT: Should adolescents with NHL be treated as old children or young adults? Hematology Am Soc Hematol Educ Program; 2007;:297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The SEER (Surveillance, Epidemiology, and End Results) data for the years 1975-1998 show that children with non-Hodgkin lymphoma (NHL) have a better treatment outcome than do adults.
  • From ages 5 through 14 years, Burkitt lymphoma is the predominant histologic subtype, whereas diffuse large B-cell lymphoma is most common in the 15- to 29-year age range.
  • It is reasonable to consider pediatric strategies for some adolescents and very young adults with NHL, and pediatric strategies are currently used to treat adults with certain subtypes of NHL (Burkitt lymphoma, lymphoblastic lymphoma).
  • However, the use of pediatric strategies in adults does not guarantee a comparable outcome, as illustrated by trials for adult lymphoblastic lymphoma.
  • Age-related differences in tumor biology have been demonstrated in anaplastic large-cell lymphoma (ALCL) and diffuse large B-cell lymphoma (DLBCL).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024643.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 62
  •  go-up   go-down


22. Kameoka J, Ichinohasama R, Inoue H, Yamamoto J, Yokoyama H, Tomiya Y, Yamada M, Ishizawa K, Harigae H, Sawai T, Sasaki T: CD26, together with cell surface adenosine deaminase, is selectively expressed on ALK-positive, but not on ALK-negative, anaplastic large cell lymphoma and Hodgkin's lymphoma. Leuk Lymphoma; 2006 Oct;47(10):2181-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD26, together with cell surface adenosine deaminase, is selectively expressed on ALK-positive, but not on ALK-negative, anaplastic large cell lymphoma and Hodgkin's lymphoma.
  • CD26/dipeptidyl peptidase IV is a cell surface antigen with multiple biological functions.
  • Although its involvement in tumor biology has been suggested, the significance of its expression in malignant lymphoma has not been clarified in detail.
  • This study examined the expression of CD26 and cell surface adenosine deaminase (ADA) in 42 cases of Hodgkin's lymphoma (HL) and T-cell lymphoma by immunohistochemistry on frozen sections.
  • CD26 was expressed in three of 14 cases of HL, in four of eight cases of anaplastic large cell lymphoma (ALCL), in two of nine cases of peripheral T-cell lymphoma, in one of six cases of lymphoblastic lymphoma and in none of three cases of adult T-cell lymphoma/leukemia.
  • Expression of cell surface ADA was fully correlated with the expression of CD26 and expression of CD26/ADA in ALCL and HL was also completely correlated with the expression of p80 and epithelial membrane antigen.
  • Of 10 CD26-positive patients, seven had fever and elevated CRP at initial diagnosis and over a median follow-up of 61 months (range, 7 - 152 months) only three survived.
  • This study suggested that CD26 is selectively expressed on ALK-positive, but not on ALK-negative, ALCL and HL.
  • This is also the first report to demonstrate that ADA is coexpressed with CD26 on the cell surface of malignant neoplasms in vivo.
  • [MeSH-major] Adenosine Deaminase / biosynthesis. Cell Membrane / enzymology. Dipeptidyl Peptidase 4 / biosynthesis. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Hodgkin Disease / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Protein-Tyrosine Kinases / biosynthesis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071493.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD3; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.4.14.5 / Dipeptidyl Peptidase 4; EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


23. Hubicki Z, Wołowicz A, Leszczyńska M: Studies of removal of palladium(II) ions from chloride solutions on weakly and strongly basic anion exchangers. J Hazard Mater; 2008 Nov 30;159(2-3):280-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Palladium(II) ions sorption from various chloride solutions of the composition: 0.1-6.0M HCl-0.00056 M Pd(II), 1.0M ZnCl(2)-0.1M HCl-0.00056 M Pd(II), 1.0M AlCl(3)-0.1M HCl-0.00056 M Pd(II) on the weakly and strongly basic anion exchangers (Varion ATM, Varion ADM and Varion ADAM) was discussed.

  • Hazardous Substances Data Bank. PALLADIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18358602.001).
  • [ISSN] 0304-3894
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anion Exchange Resins; 0 / Chlorides; 0 / Solutions; 5TWQ1V240M / Palladium
  •  go-up   go-down


24. Elenitoba-Johnson KS, Crockett DK, Schumacher JA, Jenson SD, Coffin CM, Rockwood AL, Lim MS: Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins. Proc Natl Acad Sci U S A; 2006 May 9;103(19):7402-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proteomic identification of oncogenic chromosomal translocation partners encoding chimeric anaplastic lymphoma kinase fusion proteins.
  • The anaplastic lymphoma kinase (ALK) on 2p23 is a tyrosine kinase that forms chimeric fusions with numerous translocation partners.
  • This approach accurately identified the nucleophosmin (NPM)-ALK fusion protein in an anaplastic large cell lymphoma (ALCL)-derived cell line carrying the t(2;5)(p23;q35), and the TPM3-ALK in a clinical biopsy of inflammatory myofibroblastic tumor (IMT) carrying the t(1;2)(q21;p23).
  • [MeSH-minor] Amino Acid Sequence. Antibodies / immunology. Base Sequence. Biopsy. Cell Line, Tumor. Humans. Immunoprecipitation. Mass Spectrometry. Molecular Sequence Data. Neoplasms, Muscle Tissue / metabolism. Nuclear Proteins / genetics. Proteomics. RNA, Messenger / genetics. Receptor Protein-Tyrosine Kinases. Tropomyosin / chemistry

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2776-80 [10383129.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1057-62 [9500471.001]
  • [Cites] J Biomol Tech. 2005 Dec;16(4):453-8 [16522868.001]
  • [Cites] Anal Chem. 2000 Feb 15;72(4):757-63 [10701260.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):377-84 [10934142.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):569-76 [11406658.001]
  • [Cites] Curr Opin Hematol. 2001 Jul;8(4):231-6 [11561161.001]
  • [Cites] Anal Chem. 2001 Dec 1;73(23):5683-90 [11774908.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):245-50 [11902580.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):7900-5 [12060738.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):685-94 [12951587.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] J Cell Physiol. 2004 Jun;199(3):330-58 [15095281.001]
  • [Cites] Nat Rev Cancer. 2004 May;4(5):361-70 [15122207.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Sep;5(9):699-711 [15340378.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):8998-9002 [2461560.001]
  • [Cites] Genetics. 1988 Nov;120(3):621-3 [2852134.001]
  • [Cites] Nucleic Acids Res. 1992 Feb 11;20(3):595-600 [1371352.001]
  • [Cites] Cancer Genet Cytogenet. 1992 Oct 15;63(2):81-8 [1423235.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Nature. 1994 Nov 10;372(6502):143-9 [7969446.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] PCR Methods Appl. 1994 Aug;4(1):S40-58 [9018326.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):439-49 [9053841.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2312-25 [9121481.001]
  • [Cites] Oncogene. 1997 May 8;14(18):2175-88 [9174053.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2456-64 [9310498.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11583-8 [9326653.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Nat Biotechnol. 1999 Jul;17(7):676-82 [10404161.001]
  • (PMID = 16651537.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / TPM3 protein, human; 0 / Tropomyosin; 117896-08-9 / nucleophosmin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC1464352
  •  go-up   go-down


25. Pich A, Fraire F, Fornari A, Bonino LD, Godio L, Bortolin P, Chiusa L, Palestro G: Intrasinusoidal bone marrow infiltration and splenic marginal zone lymphoma: a quantitative study. Eur J Haematol; 2006 May;76(5):392-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrasinusoidal bone marrow infiltration and splenic marginal zone lymphoma: a quantitative study.
  • Intrasinusoidal infiltration (ISI) is a pattern of invasion that is rarely found on bone marrow (BM) biopsies, and is considered as a hallmark of splenic marginal zone cell lymphoma (SMZL).
  • We analysed BM biopsies showing intrasinusoidal infiltration from 54 consecutive patients with different types of lymphoma to verify if ISI quantity was a diagnostic criterion for SMZL.
  • There were 35 primary splenic lymphoma (PSL) and 19 non-PSL; 28 SMZL, three non-splenic MZL, six mantle cell, six small lymphocytic, four follicular, four diffuse large B cell, one peripheral T cell, one lymphoplasmacytic and one anaplastic large-cell lymphoma.
  • No difference in ISI quantity was found among the lymphoma subtypes, either in PSL (P = 0.74) or non-PSL (P = 0.3).
  • [MeSH-major] Bone Marrow / pathology. Bone Marrow Neoplasms / secondary. Lymphoma, Non-Hodgkin / pathology. Splenic Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Bone Marrow Examination / methods. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Organ Size

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Haematol. 2006 Oct;77(4):360; author reply 361 [16961729.001]
  • (PMID = 16480431.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


26. Bhagavathi S, Wilson JD: Primary central nervous system lymphoma. Arch Pathol Lab Med; 2008 Nov;132(11):1830-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma.
  • Primary central nervous system lymphoma (PCNSL) is an uncommon extranodal non-Hodgkin lymphoma.
  • Diffuse large B-cell lymphomas constitute most PCNSLs, whereas T-cell, low-grade, anaplastic, and Hodgkin lymphomas are rarely encountered.
  • The morphology of PCNSL shows a characteristic angiocentric pattern and is positive for B-cell markers by immunohistochemistry.
  • The differential diagnosis of PCNSL includes central nervous system gliomas, metastatic tumors, demyelinating disorders, subacute infarcts, and space-occupying lesions due to an infectious etiology.
  • The understanding of the molecular mechanisms involved in the pathogenesis of PCNSL and the identification of molecular biomarkers have lagged behind that of systemic nodal lymphomas.
  • Primary central nervous system lymphomas are treated with combined radiotherapies and chemotherapies.
  • The prognosis for PCNSL is worse than for other extranodal lymphomas.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18976024.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


27. Adelusola KA, Titiloye NA, Rotimi O, Durosinmi M: Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians. Afr Health Sci; 2009 Sep;9(3):174-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein Barr virus latent membrane protein-1 in Hodgkin's lymphoma in Nigerians.
  • BACKGROUND: The burden of lymphomas on the health care system in Nigeria is enormous.
  • Correct diagnosis and identification of aetiological factor are important steps in reducing this burden.
  • Epstein-Barr virus latent membrane protein-1 (LMP-1), CD15 and CD30 immunohistochemistry was also performed.
  • The rest were non-Hodgkin's lymphoma (2 diffuse large B-cell and 1 null cell ALCL).
  • 60% of the tumour was EBV positive, all of the MC subtype.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Hodgkin Disease / virology. Viral Matrix Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Antigens, CD15 / immunology. Antigens, CD30 / immunology. Biomarkers, Tumor / immunology. Child. Female. Hospitals, Teaching. Humans. Immunohistochemistry. Immunophenotyping. Male. Nigeria. Young Adult

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Pathol. 2000 Oct;53(5):262-9 [11091850.001]
  • [Cites] Histopathology. 2008 May;52(6):775-7 [18439160.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2114-20 [12796376.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):566-73 [12808062.001]
  • [Cites] Lancet Oncol. 2004 Jan;5(1):11-8 [14700604.001]
  • [Cites] Br J Haematol. 2004 May;125(3):267-81 [15086409.001]
  • [Cites] Cancer. 2004 May 1;100(9):1902-8 [15112271.001]
  • [Cites] Afr J Med Med Sci. 1992 Oct;21(1):79-83 [1288248.001]
  • [Cites] Leukemia. 1994 Apr;8 Suppl 1:S77-82 [8152310.001]
  • [Cites] Br J Haematol. 2005 Jun;129(5):615-7 [15916683.001]
  • [Cites] Eur J Haematol Suppl. 2005 Jul;(66):55-62 [16007870.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):747-55 [16084943.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2444-51 [15941916.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7604-13 [16186595.001]
  • [Cites] Mutat Res. 2000 Apr;462(2-3):395-405 [11523539.001]
  • (PMID = 20589147.001).
  • [ISSN] 1729-0503
  • [Journal-full-title] African health sciences
  • [ISO-abbreviation] Afr Health Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Uganda
  • [Chemical-registry-number] 0 / Antigens, CD15; 0 / Antigens, CD30; 0 / Biomarkers, Tumor; 0 / EBV-associated membrane antigen, Epstein-Barr virus; 0 / Viral Matrix Proteins
  • [Other-IDs] NLM/ PMC2887026
  • [Keywords] NOTNLM ; Epstein-Barr virus / Hodgkin's lymphoma in Nigerians
  •  go-up   go-down


28. Sridharan M, Prasad KJ, Ngendahimana A, Zeller M: 2,2-Dimethyl-2,3-dihydro-pyrano[2,3-a]carbazol-4(11H)-one. Acta Crystallogr Sect E Struct Rep Online; 2008;64(Pt 11):o2155
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The title compound, C(17)H(15)NO(2), was prepared from 1-hydroxy-carbazole and 3,3-dimethyl-acrylic acid with a mixture of AlCl(3) and POCl(3) as the cyclization catalyst.
  • In the crystal structre, strong N-H⋯O hydrogen bonds and weaker C-H⋯π inter-actions occur, and a slipped π-π stacking inter-action [centroid-centroid separation = 3.8425 (8) Å] is also observed.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Rev. 2002 Nov;102(11):4303-427 [12428991.001]
  • [Cites] Acta Crystallogr Sect E Struct Rep Online. 2008;64(Pt 11):o2157 [21581017.001]
  • [Cites] Acta Crystallogr Sect E Struct Rep Online. 2008;64(Pt 11):o2156 [21581016.001]
  • [Cites] Acta Crystallogr A. 2008 Jan;64(Pt 1):112-22 [18156677.001]
  • (PMID = 21581015.001).
  • [ISSN] 1600-5368
  • [Journal-full-title] Acta crystallographica. Section E, Structure reports online
  • [ISO-abbreviation] Acta Crystallogr Sect E Struct Rep Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2959512
  •  go-up   go-down


29. Zheng YY, Chen G, Zhou XG, Zhang SH, Zhang YN: [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Morphologic and immunophenotypic analysis of angioimmunoblastic T-cell lymphoma].
  • OBJECTIVE: To study the morphologic and immunophenotypic features of angioimmunoblastic T-cell lymphoma (AITL), as well as the origin of the proliferative follicular dendritic cells (FDCs) in AITL.
  • Cases of peripheral T-cell lymphoma, unspecified, extranodal NK/T-cell lymphoma, nasal-type, enteropathy-type T-cell lymphoma, anaplastic large cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma and reactive lymphoid proliferation were selected as controls.
  • RESULTS: Amongst the 29 cases of AITL studied, 75.9% (22/29) showed aberrant expression of CD10, while all except one of the controlled cases were negative, 82.8% (24/29) of the AITL cases expressed CXCL13, while all cases of peripheral T-cell lymphoma, unspecified were negative.
  • As for bcl-6 staining, although the highest percentage of bcl-6-positive cells was observed in AITL, the expression pattern was not useful in differentiating AITL from peripheral T-cell lymphoma, unspecified and lymphoid reaction.
  • Two of the cases, which contained obvious germinal centers, had the follicular dendritic cell meshwork extending beyond the lymphoid follicles.
  • [MeSH-major] Chemokine CXCL13 / metabolism. Dendritic Cells, Follicular / pathology. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell, Peripheral / pathology. Neprilysin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575853.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CXCL13 protein, human; 0 / Chemokine CXCL13; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Receptors, Complement 3d; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


30. Reimer P, Rüdiger T, Wilhelm M: The role of high-dose therapy in peripheral T-cell lymphomas. Clin Lymphoma Myeloma; 2006 Mar;6(5):373-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of high-dose therapy in peripheral T-cell lymphomas.
  • Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous group of non-Hodgkin's lymphomas.
  • With few exceptions (eg, anaplastic large-cell lymphoma expressing the anaplastic lymphoma kinase), PTCLs have generally been reported to have a worse prognosis compared with B-cell lymphomas.
  • Despite the poor outcome after conventional therapy, the impact of high-dose therapy with autologous or allogeneic stem cell transplantation (SCT) in these rare diseases is poorly defined mainly because of the lack of prospective PTCL-restricted studies.
  • Most data exist for high-dose therapy with autologous SCT in relapsing or refractory disease.
  • Because most studies showed similar results for PTCL compared with aggressive B-cell lymphomas in which high-dose therapy with autologous SCT is accepted as standard therapy, this approach seems appropriate in relapsing or refractory PTCL.
  • Results for high-dose therapy with autologous SCT as first-line therapy mainly rely on studies on aggressive lymphomas that also included lymphomas of the T-cell phenotype.
  • Our own recently published PTCL-restricted prospective study confirmed the feasibility with only moderate toxicity and a good response rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, T-Cell, Peripheral / mortality. Lymphoma, T-Cell, Peripheral / therapy. Stem Cell Transplantation / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16640812.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 62
  •  go-up   go-down


31. Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, Senter PD, Wahl AF: In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res; 2005 Jan 15;11(2 Pt 1):843-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
  • Conjugation of monomethyl auristatin E (MMAE) to the anti-CD30 monoclonal antibody (mAb), cAC10, produced a selective and potent ADC against CD30(+) anaplastic large cell lymphoma and Hodgkin's disease models.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antigens, CD30 / immunology. Hodgkin Disease. Immunoconjugates / therapeutic use. Lymphoma, Large-Cell, Anaplastic. Oligopeptides / therapeutic use

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15701875.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Anti-Idiotypic; 0 / Antibodies, Monoclonal; 0 / Antigens, CD30; 0 / Disulfides; 0 / Hydrazones; 0 / Immunoconjugates; 0 / Oligopeptides; 0 / monomethyl auristatin E
  •  go-up   go-down


32. Saint-Blancard P, Harket A, Defuentes G, de Fonclare AL, Bonnichon A, de Revel T, Berets O, Margery J: [Primary pleural lymphoma: a late complication of pleural decortication for tuberculosis: two cases in western countries]. Rev Pneumol Clin; 2007 Sep;63(4):277-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary pleural lymphoma: a late complication of pleural decortication for tuberculosis: two cases in western countries].
  • [Transliterated title] Lymphome pleural primitif: une complication tardive de la collapsothérapie chez des anciens tuberculeux. A propos de deux nouveaux cas.
  • Pleural lymphomas after a long standing pyothorax due to pleuropulmonary tuberculosis are now well identified, but rarely observed in Europe.
  • Histology revealed high-grade lymphomas, diffuse large B-cell lymphoma and anaplastic lymphoma.
  • Serology for Epstein-Barr virus was positive.
  • Pleural lymphomas are an established complication of artificial pneumothorax.
  • Epstein-Barr virus is known to play a crucial role in the pathogenesis, but despite the large number of artificial pneumothorax operations, these lymphomas remain rare, suggesting additional oncogenic factors.
  • [MeSH-major] Lymphoma, Non-Hodgkin / etiology. Pleural Neoplasms / etiology. Pneumothorax, Artificial / adverse effects. Postoperative Complications. Tuberculosis, Pleural / surgery. Tuberculosis, Pulmonary / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, Viral / blood. Empyema, Tuberculous / surgery. Female. Herpesvirus 4, Human / immunology. Humans. Lymphoma, Large B-Cell, Diffuse / etiology. Lymphoma, Large-Cell, Anaplastic / etiology. Male

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17978741.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antigens, Viral
  •  go-up   go-down


33. Winhoven SM, Murugesan S, Coulson IH: Solitary CD30+ anaplastic large cell lymphoma of the eyelid showing regression. Br J Ophthalmol; 2005 Mar;89(3):385
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary CD30+ anaplastic large cell lymphoma of the eyelid showing regression.
  • [MeSH-major] Eyelid Neoplasms / pathology. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Antigens, CD30 / immunology. Humans. Male. Neoplasm Regression, Spontaneous

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Blood. 1997 Jul 1;90(1):354-71 [9207472.001]
  • [Cites] Br J Dermatol. 2003 Mar;148(3):580-6 [12653754.001]
  • (PMID = 15722323.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30
  • [Other-IDs] NLM/ PMC1772546
  •  go-up   go-down


34. de Leval L, Bisig B, Thielen C, Boniver J, Gaulard P: Molecular classification of T-cell lymphomas. Crit Rev Oncol Hematol; 2009 Nov;72(2):125-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular classification of T-cell lymphomas.
  • T-cell neoplasms encompass a heterogeneous group of relatively rare disease entities.
  • This review, focused on lymphoblastic tumors (T-ALL/LBL) and nodal-based peripheral T-cell lymphomas (PTCL), summarizes recent advances in the molecular characterization of these diseases.
  • Angioimmunoblastic T-cell lymphoma (AITL), one of the most common PTCL entities, comprises neoplastic cells with a molecular signature similar to normal follicular helper T cells, and this cellular derivation might account for several of the peculiar aspects of this disease.
  • Except in ALK-positive anaplastic large cell lymphoma, defined by ALK gene fusions, chromosomal translocations are otherwise rare in PTCLs, but some recurrent rearrangements might be associated with distinct lymphoma subtypes.
  • [MeSH-major] Biomarkers, Tumor / genetics. Lymphoma, T-Cell / classification. Lymphoma, T-Cell / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19233683.001).
  • [ISSN] 1879-0461
  • [Journal-full-title] Critical reviews in oncology/hematology
  • [ISO-abbreviation] Crit. Rev. Oncol. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 111
  •  go-up   go-down


35. Zhang Q, Wang HY, Liu X, Wasik MA: STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat Med; 2007 Nov;13(11):1341-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Amino Acid Motifs / genetics. Base Sequence. Catalytic Domain / genetics. Cell Line, Transformed. Cell Line, Tumor. Down-Regulation / genetics. Humans. Jurkat Cells. Lymphoma, Large-Cell, Anaplastic / enzymology. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, T-Cell / enzymology. Lymphoma, T-Cell / genetics. Molecular Sequence Data. Protein Binding / genetics. Receptor Protein-Tyrosine Kinases

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922009.001).
  • [ISSN] 1078-8956
  • [Journal-full-title] Nature medicine
  • [ISO-abbreviation] Nat. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA89194; United States / NCI NIH HHS / CA / R01-CA96856
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / STAT5 Transcription Factor; 0 / STAT5A protein, human; 0 / Tumor Suppressor Proteins; 117896-08-9 / nucleophosmin; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


36. Choi IH, Kim JN, Kwon YM: Effects of chemical treatments on pH and bacterial population in poultry litter: a laboratory experiment. Br Poult Sci; 2008 Sep;49(5):497-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2. Litter obtained from poultry houses was treated with three chemical treatments (alum, AlCl(3) and FeSO(4)) at the same concentration (8 g/100 g litter), while untreated litter served as a control.
  • However, a significant difference in gram-negative bacteria did not exist among chemical treatments at 0, 1 and 2 weeks.
  • 4. These results suggest that the reduction in total aerobic bacteria and gram-negative bacteria populations is highly related to a decrease in litter pH, and acidifying treatment (alum, AlCl(3) and FeSO(4)) of poultry litter may serve as a means to help the reduction in pathogen populations and to improve economical benefits under commercial production conditions.

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. ALUMINUM SULFATE .
  • Hazardous Substances Data Bank. ALUM, POTASSIUM .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • Hazardous Substances Data Bank. FERROUS SULFATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18836894.001).
  • [ISSN] 1466-1799
  • [Journal-full-title] British poultry science
  • [ISO-abbreviation] Br. Poult. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alum Compounds; 0 / Aluminum Compounds; 0 / Chlorides; 0 / Ferrous Compounds; 10043-01-3 / aluminum sulfate; 39R4TAN1VT / ferrous sulfate; 3CYT62D3GA / aluminum chloride
  •  go-up   go-down


37. Zidane F, Drogui P, Lekhlif B, Bensaid J, Blais JF, Belcadi S, El Kacemi K: Decolourization of dye-containing effluent using mineral coagulants produced by electrocoagulation. J Hazard Mater; 2008 Jun 30;155(1-2):153-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The best performances of dye removal were obtained with C(2) having a chemical structure comprised of a mixture of polymeric specie (Al45O45(OH)45Cl) and monomeric species (AlCl(OH)2.2H2O and Al(OH)3).

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. SODIUM HYDROXIDE .
  • Hazardous Substances Data Bank. SODIUM CHLORIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18155356.001).
  • [ISSN] 0304-3894
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Coloring Agents; 0 / Minerals; 0 / Triazines; 0 / Water Pollutants, Chemical; 451W47IQ8X / Sodium Chloride; 55X04QC32I / Sodium Hydroxide; 61931-52-0 / Procion Red HE-7B
  •  go-up   go-down


38. McBride WJ, Sharkey RM, Karacay H, D'Souza CA, Rossi EA, Laverman P, Chang CH, Boerman OC, Goldenberg DM: A novel method of 18F radiolabeling for PET. J Nucl Med; 2009 Jun;50(6):991-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A solution of AlCl(3).6H(2)O in a pH 4.0 sodium-acetate buffer was mixed with an aqueous solution of (18)F to form the Al(18)F complex.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443594.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / 1 R43 EB003751-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes
  •  go-up   go-down


39. Vinogradova IuE, Lutsenko IN, Kaplanskaia IB, Vorob'ev IA, Samoĭlova RS, Gorgidze LA, Ryzhikova NA, Valiev TT, Giliazitdinova EA, Dzhulakian UL, Egorova EK, Zvonkov EE, Krasil'nikova BB, Magomedova AU, Margolin OV, Mar'in DS, Kremenetskaia AM, Kravchenko SK, Vorob'ev AI: [Efficacy of therapy of different variants of anaplastic large T-cell lymphomas]. Ter Arkh; 2008;80(7):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of therapy of different variants of anaplastic large T-cell lymphomas].
  • AIM: To compare efficacy of NHL-BFM-90 and CHOP-like courses in the treatment of anaplastic large cell lymphoma (ALCL).
  • MATERIAL AND METHODS: Twenty-two patients with ALCL participated in the study.
  • The diagnosis was made basing on the findings of clinical, device, morphological, immunohistochemical and molecular-genetic examinations with application of a panel of monoclonal antibodies to CD30, ALK, CD3, CD4, CDS, CD7, CD34, CD15, CD68, CD20, CD45RO, CD45RA, Ki-67.
  • 14 cases of 22 were negative by kinase of anaplastic lymphocytes (ALK-) and 8 were positive (ALK+).
  • Mean age of ALK-ALCL patients was 39.6 +/- 4.1 years, of ALK+ALCL patients - 23.4 +/- 2.6 years.
  • All 14 patients treated according to NHL-BFM-90 had ALCL stages III-IV with B-symptoms.
  • Of 8 ALCL patients treated initially according to other schemes, a complete remission was achieved in 4 patients (2 had stage II).
  • Four patients who had failed to achieve complete remission died of the disease progression.
  • CONCLUSION: ALCL occurs more frequently in young and middle-aged patients.
  • The disease has an aggressive course with rapid generalization.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large-Cell, Anaplastic / drug therapy

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18763592.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.5.1.1 / Asparaginase; Q573I9DVLP / Leucovorin; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; BEACOPP protocol; CHOP protocol; MACOP-B protocol; PVDA protocol
  •  go-up   go-down


40. Pan GB, Freyland W: In situ STM investigation of spinodal decomposition and surface alloying during underpotential deposition of Cd on Au(111) from an ionic liquid. Phys Chem Chem Phys; 2007 Jul 7;9(25):3286-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In situ STM investigation of spinodal decomposition and surface alloying during underpotential deposition of Cd on Au(111) from an ionic liquid.
  • The electrodeposition and anodic dissolution of Cd on Au(111) in an acidic chloroaluminate ionic liquid (MBIC-AlCl(3), 42 : 58 mol%) have been investigated by cyclic voltammetry and in situ STM.
  • In the Cd underpotential deposition region, various nanostructures can be distinguished.
  • At a potential of 0.95 V vs. Al/Al(iii), a transformation from a well ordered AlCl(4)(-) adlayer to a ( radical3 x radical19) superstructure, presumably due to Cd-AlCl(4)(-) coadsorption, is observed.
  • Reducing the potential to 0.45 V, surface alloying of Cd and Au occurs, which is evidenced for the first time by typical spinodal structures occurring both during deposition and dissolution of the surface alloy layer having a hexagonal structure.
  • At still lower potentials below 0.21 V, a layer-by-layer growth of bulk Cd sets in.

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17579737.001).
  • [ISSN] 1463-9076
  • [Journal-full-title] Physical chemistry chemical physics : PCCP
  • [ISO-abbreviation] Phys Chem Chem Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alloys; 0 / Aluminum Compounds; 0 / Cations; 0 / Chlorides; 0 / Ionic Liquids; 00BH33GNGH / Cadmium; 3CYT62D3GA / aluminum chloride; 7440-57-5 / Gold
  •  go-up   go-down


41. Dey P, Amir T, Al Jassar A, Al Shemmari S, Jogai S, Bhat M G, Al Quallaf A, Al Shammari Z: Combined applications of fine needle aspiration cytology and flow cytometric immunphenotyping for diagnosis and classification of non Hodgkin lymphoma. Cytojournal; 2006;3:24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined applications of fine needle aspiration cytology and flow cytometric immunphenotyping for diagnosis and classification of non Hodgkin lymphoma.
  • AIMS AND OBJECTIVES: In this present study we have evaluated the feasibility of sub-classification of non-Hodgkin's lymphoma (NHL) cases according to World Health Organization's (WHO) classification on fine needle aspiration cytology (FNAC) material along with flow cytometric immunotyping (FCI) as an adjunct.
  • MATERIALS AND METHODS: In this five years study, only cases suggested or confirmed as NHL by FNAC were selected and FCI was performed with a complete panel of antibodies (CD3, CD2, CD 4, CD5, CD8, CD7, CD10, CD19, CD20, CD23, CD45, kappa and lambda) by dual color flow cytometry.
  • The cases were classified on FNAC as predominant small cells (12), mixed small and large cells (5) and large cells (26).
  • Combined FNAC and FCI data helped to diagnose 9 cases of small lymphocytic lymphoma (SLL), 2 cases of mantle cell lymphoma (MCL), 4 cases of follicular lymphoma (FL), 17 cases of diffuse large B lymphoma (DLBL) and 6 cases of lymphoblastic lymphoma.
  • Histopathology diagnosis was available in 31 cases of NHL out of which there were 14 recurrent and 17 cases of primary NHL.
  • Out of 15 DLBL cases diagnosed on FCI and FNAC, histology confirmed 14 cases and one of these cases was diagnosed as Burkitt's lymphoma on histology.
  • Histology diagnosis was given as DLBL (1), SLL (1), anaplastic large cell lymphoma (1) and FL transformed into large cell NHL (1).
  • Many of the subtypes of NHL such as FL and MCL which were previously recognized as a pure morphologic entity can be diagnosed by combined use of FNAC and FCI.
  • Other ancillary investigations such as chromosomal changes, cell proliferation markers etc. may be helpful in this aspect.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Cytopathol. 1998 Oct;19(4):274-8 [9784991.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3601-9 [10339464.001]
  • [Cites] Histopathology. 2000 Jan;36(1):69-86 [10632755.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):451-7 [10911803.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1792-9 [11100059.001]
  • [Cites] Diagn Cytopathol. 2001 Apr;24(4):229-32 [11285616.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):251-6 [11933272.001]
  • [Cites] Diagn Cytopathol. 2002 Dec;27(6):340-2 [12451563.001]
  • [Cites] Diagn Cytopathol. 2003 Apr;28(4):191-5 [12672094.001]
  • [Cites] Diagn Cytopathol. 1992;8(5):551-2 [1396035.001]
  • [Cites] Cancer. 2005 Dec 25;105(6):432-42 [16222688.001]
  • [Cites] Diagn Cytopathol. 1996 Nov;15(4):352-7 [8982596.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1771-9 [8781434.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):72-7 [2293872.001]
  • [Cites] Cytopathology. 2006 Oct;17(5):275-87 [16961657.001]
  • [Cites] Acta Cytol. 1990 May-Jun;34(3):329-36 [2343687.001]
  • [Cites] Acta Cytol. 1984 May-Jun;28(3):337-45 [6587711.001]
  • [Cites] Diagn Cytopathol. 1995 May;12(3):201-7 [7621714.001]
  • [Cites] Acta Cytol. 1993 Sep-Oct;37(5):745-6 [8362592.001]
  • [Cites] Histopathology. 1994 Dec;25(6):517-36 [7698729.001]
  • (PMID = 17069647.001).
  • [ISSN] 1742-6413
  • [Journal-full-title] CytoJournal
  • [ISO-abbreviation] Cytojournal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1634871
  •  go-up   go-down


42. Wang QQ, Wang DX, Yang HB, Huang ZT, Wang MX: Synthesis, structure and molecular recognition of functionalised tetraoxacalix[2]arene[2]triazines. Chemistry; 2010 Jun 25;16(24):7265-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AlCl(3)-mediated deallylation and debenzylation reactions afforded the lower-rim dihydroxy-substituted tetraoxacalix[2]arene[2]triazine derivatives 11 and 13 in good yields.
  • The dihydroxylated tetraoxacalix[2]arene[2]triazine 13 b, which gives a mixture of monomer and dimer in solution according to a diffusion NMR spectroscopy study, adopts a 1,3-alternate conformation and forms a cyclic tetrameric assembly in the solid state due to the formation of intermolecular hydrogen-bonding networks.
  • This dihydroxylated macrocyclic host molecule, a hydrogen-bond donor macrocycle with a V-shaped cleft, interacts with 2,2'-bipyridine, 4,4'-bipyridine and 1,10-phenanthroline guests.
  • Hydrogen-bonding interactions, along with other non-covalent interactions, such as lone-pair-electron-pi and C-H...pi interactions, were found to be the driving force for the formation of host-guest complexes.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20468032.001).
  • [ISSN] 1521-3765
  • [Journal-full-title] Chemistry (Weinheim an der Bergstrasse, Germany)
  • [ISO-abbreviation] Chemistry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Macrocyclic Compounds; 0 / Triazines; 0 / tetraoxacalix(2)arene(2)triazine; 130036-26-9 / Calixarenes
  •  go-up   go-down


43. Kim IS, Shin SY, Kim YS, Kim HY, Yoon HS: Expression of a glutathione reductase from Brassica rapa subsp. pekinensis enhanced cellular redox homeostasis by modulating antioxidant proteins in Escherichia coli. Mol Cells; 2009 Nov 30;28(5):479-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The BrGR-expressing E. coli cells showed increased GR activity and tolerance to H(2)O(2), menadione, and heavy metal (CdCl(2), ZnCl(2) and AlCl(2))-mediated growth inhibition.
  • A proteomic analysis demonstrated the higher level of induction of proteins involved in glycolysis, detoxification/oxidative stress response, protein folding, transport/binding proteins, cell envelope/porins, and protein translation and modification when exposed to H(2)O(2) stress.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. MENADIONE .
  • Hazardous Substances Data Bank. CADMIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. ZINC, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936628.001).
  • [ISSN] 0219-1032
  • [Journal-full-title] Molecules and cells
  • [ISO-abbreviation] Mol. Cells
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Proteome; 0 / Recombinant Proteins; 00BH33GNGH / Cadmium; 723JX6CXY5 / Vitamin K 3; BBX060AN9V / Hydrogen Peroxide; EC 1.8.1.7 / Glutathione Reductase; J41CSQ7QDS / Zinc
  •  go-up   go-down


44. Ye K: Nucleophosmin/B23, a multifunctional protein that can regulate apoptosis. Cancer Biol Ther; 2005 Sep;4(9):918-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NPM-ALK, an aberrant fusion protein produced from t(2;5) translocation in anaplastic large cell lymphoma (ALCL), fuses the N-terminus of B23 to the intracellular tyrosine kinase domain of ALK, provoking lymphomas by stimulating various mitogenic proteins including PI 3-kinase and PLC-gamma1.
  • Overexpression of B23 inhibits apoptosis, while knockdown of B23 induces cell death.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103750.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS045627
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / Phosphatidylinositol Phosphates; 0 / Phosphoproteins; 0 / phosphatidylinositol 3,4,5-triphosphate; 117896-08-9 / nucleophosmin; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 3.1.- / Deoxyribonucleases; EC 3.1.- / caspase-activated deoxyribonuclease
  • [Number-of-references] 71
  •  go-up   go-down


45. Punnoose LR, Roh JD, Hu S, Udell JA, Wagle N, Kirshenbaum JM, Lacasce AS: Cardiac presentation of anaplastic large-cell lymphoma. J Clin Oncol; 2010 Jul 1;28(19):e314-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac presentation of anaplastic large-cell lymphoma.
  • [MeSH-major] Heart / physiopathology. Heart Neoplasms / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Myocardium / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Tachycardia / physiopathology. Troponin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20516445.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Troponin
  •  go-up   go-down


46. Yamamoto H, Kohashi K, Oda Y, Tamiya S, Takahashi Y, Kinoshita Y, Ishizawa S, Kubota M, Tsuneyoshi M: Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene. Pathol Int; 2006 Oct;56(10):584-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of human herpesvirus-8 and Epstein-Barr virus in inflammatory myofibroblastic tumor with anaplastic large cell lymphoma kinase fusion gene.
  • Some populations of IMT have anaplastic large cell lymphoma kinase (ALK) gene rearrangements.
  • Immunohistochemically, 15 cases were ALK positive and six were negative.
  • These results suggest that IMT may be a heterogeneous group in terms of pathogenesis, and EBV and HHV-8 do not play a major role in the pathogenesis of ALK-positive tumor.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16984614.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Nuclear Proteins; 0 / Oncogene Proteins, Fusion; 0 / TPM3 protein, human; 0 / TPM4 protein, human; 0 / Tropomyosin; 0 / latency-associated nuclear antigen; 114899-12-6 / Clathrin Heavy Chains; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


47. Melikian AL, Nikitin EA, Kaplanskaia IB, Frank GA: [Paraneoplastic lymphadenopathy]. Ter Arkh; 2007;79(8):44-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: In a retrospective analysis of 457 patients observed in Hematology Research Center of the RF in 1994-2004, and diagnosed as having non-malignant lymphadenopathies, we identified 40 patients in whom the second or third biopsy showed lymphoma.
  • Nineteen patients (47.5%) had Hodgkin's lymphomas, 11 (27.5%)--B-cell lymphomas and 10 (25%) T-cell lymphomas.
  • RESULTS: In patients subsequently diagnosed with Hodgkin's lymphoma there were 4 repeating histologic patterns in paraneoplastic lymph nodes: sinus histiocytosis (7 patients, 37%), paracortical reaction with numerous plasma cells and macrophages (7 patients, 37%), marked fibrotic changes (4 patients, 21%) and necrotizing lesions (3 patients, 16%).
  • Amongst patients with B-cell lymphomas 7 had follicular lymphomas, 3--diffuse large B-cell lymphomas and 1--mantle cell lymphoma.
  • In 5 patients with follicular lymphoma initially diagnosed as having follicular hyperplasia, retrospective analysis and immunohistochemistry showed partial involvement of lymph nodes with lymphoma.
  • Amongst patients with T-cell lymphomas 5 had undetermined peripheral T-cell lymphomas, 2--anaplastic large cell lymphomas, 1--angioimmunoblastic lymphoma, 1--hepatolienal lymphoma and 1--Lennert's lymphoma.
  • Clonal rearrangements of gamma-chain T-cell receptor genes were found in 2 patients from 3 tested.
  • CONCLUSION: Histologic patterns in lymph nodes not involved by lymphomas in patients with lymphomas are not random.
  • While sinus histiocytosis and necrosis are universal findings, some patterns are disease specific.
  • Paracortical hyperplasia is typical for T-cell lymphomas, prominent fibrosis--for Hodgkin's lymphoma.
  • From practical point of view, finding of necrosis, prominent sinus histiocytosis, or prominent fibrosis of a lymph node in the absence of a history of chronic lymphadenitis or inflammation in the draining area should be considered as possible indication to second biopsy.
  • Interpretation of such paraneoplastic phenomena as paracortical hyperplasia and formation of epithelioid-cell granulemas is not easy and must consider context of a clinical picture.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Biopsy. Diagnosis, Differential. Diagnostic Errors. Diaphragm. Female. Follow-Up Studies. Humans. Lymph Nodes / pathology. Male. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926471.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


48. Pena LB, Zawoznik MS, Tomaro ML, Gallego SM: Heavy metals effects on proteolytic system in sunflower leaves. Chemosphere; 2008 Jun;72(5):741-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was recently demonstrated that under severe Cd stress sunflower (Helianthus annuus L.) proteasome activity is reduced and this results in accumulation of oxidized proteins.
  • Ten days old sunflower plants were transferred to hydroponic culture solutions devoid (control) or containing 100 microM of AlCl(3), CoCl(2), CuCl(2), CrCl(3), HgCl(2), NiCl(2), PbCl(2) or ZnCl(2) and analyzed for protein oxidative damage and proteolytic activities.

  • Hazardous Substances Data Bank. Water .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18462779.001).
  • [ISSN] 0045-6535
  • [Journal-full-title] Chemosphere
  • [ISO-abbreviation] Chemosphere
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Metals, Heavy; 0 / Plant Proteins; 0 / Ubiquitin; 059QF0KO0R / Water; EC 3.4.- / Peptide Hydrolases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


49. Bakshi NA, Finn WG, Schnitzer B, Valdez R, Ross CW: Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma. Arch Pathol Lab Med; 2007 May;131(5):742-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma.
  • Fascin is a sensitive marker for classical Reed-Sternberg cells and has a high negative predictive value for diagnosis of classical Hodgkin lymphoma (CHL).
  • Fascin has been used to distinguish CHL from non-Hodgkin lymphoma.
  • Recently, it was shown that fascin might not help differentiate CHL from anaplastic large cell lymphoma (ALCL).
  • Moreover, fascin has not been extensively studied in the context of other large cell lymphomas.
  • OBJECTIVE: To analyze fascin expression in diffuse large B-cell lymphoma (DLBCL) and also reexamine its usefulness in discriminating CHL from ALCL.
  • DESIGN: Formalin-fixed, paraffin-embedded tissue samples from 41 cases of DLBCL, 30 cases of CHL, and 30 cases of ALCL were analyzed.
  • Fascin expression was compared across each type of lymphoma with additional correlation between fascin positivity and ALK-1 expression in ALCL performed.
  • RESULTS: Only 6 (14.6%) of 41 cases of DLBCL stained positively for fascin, with most neoplastic large cells exhibiting a weak staining pattern.
  • Fifteen (50%) of 30 cases of ALCL showed positivity for fascin, with most large cells staining strongly.
  • All 30 cases of CHL demonstrated intense positive staining.
  • Sixty percent of fascin-positive ALCLs were positive for ALK-1, while 66.7% of fascin-negative ALCLs were positive for ALK-1.
  • CONCLUSIONS: Fascin is highly sensitive for CHL and has a very high negative predictive value (100% in this series) for distinguishing CHL from DLBCL or ALCL.
  • However, the specificity and positive predictive value for fascin are much higher in distinguishing CHL from DLBCL than in distinguishing CHL from ALCL.
  • Expression of fascin appears more useful in the differential diagnosis of CHL versus DLBCL than in the differential diagnosis of CHL versus ALCL.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carrier Proteins / biosynthesis. Hodgkin Disease / metabolism. Lymphoma, B-Cell / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. Microfilament Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Predictive Value of Tests. Sensitivity and Specificity


50. Opiso E, Sato T, Yoneda T: Adsorption and co-precipitation behavior of arsenate, chromate, selenate and boric acid with synthetic allophane-like materials. J Hazard Mater; 2009 Oct 15;170(1):79-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solutions containing 100 or 150 mmol of AlCl(3)x6H(2)O were mixed to 100 mmol of Na(4)SiO(4) and the pH were adjusted to 6.4+/-0.3.

  • Hazardous Substances Data Bank. SELENIUM COMPOUNDS .
  • Hazardous Substances Data Bank. SODIUM SELENATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19493614.001).
  • [ISSN] 1873-3336
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aluminum Silicates; 0 / Boric Acids; 0 / Chromates; 0 / Environmental Pollutants; 0 / Selenium Compounds; HV0Y51NC4J / Selenic Acid; R57ZHV85D4 / boric acid
  •  go-up   go-down


51. Macák J, Plank L: [Non-Hodgkin's lymphomas (from Rappaport to WHO 2001 and nowadays). Review]. Cesk Patol; 2007 Apr;43(2):39-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's lymphomas (from Rappaport to WHO 2001 and nowadays). Review].
  • In the last decades, considerable changes in the classification of lymphomas have been made.
  • The authors describe some differences in immunophenotype in certain entities: chronic lymphocytic leukaemia/small lymphocytic lymphoma--CLL/SLL, follicular lymphoma--FL, mantle cell lymphoma--MCL, diffuse large B-cell lymphoma--DLBCL, and anaplastic large cell lymphoma--ALCL, mainly with respect to prognosis.
  • The authors point out to heterogeneity within the individual types of lymphomas from the point of view of morphology, immunohistochemistry and molecular biology.
  • Recently it has been shown, that differences in prognosis are not limited to individual nosologic entities, but also may be found within the particular category of lymphoma.
  • The cases with unmutated VH segment display progressive disease which is in contrast to cases with the same morphology but with mutated VH segment.
  • [MeSH-major] Lymphoma, Non-Hodgkin / classification

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17623975.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 56
  •  go-up   go-down


52. Ait-Tahar K, Damm-Welk C, Burkhardt B, Zimmermann M, Klapper W, Reiter A, Pulford K, Woessmann W: Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood; 2010 Apr 22;115(16):3314-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk.
  • Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) constitutes an ideal model disease to study tumor-specific immune responses.
  • Although antibodies and T-cell responses to ALK have previously been detected in ALK-positive ALCL patients, their prognostic significance is unknown.
  • We investigated a large cohort of uniformly treated ALK-positive pediatric ALCL patients to ascertain whether the titers of preexisting ALK autoantibodies correlated with clinical and histologic characteristics, tumor dissemination, and patient outcome.
  • Our results provide the first clinical evidence that a robust preexisting immune response to an oncoantigen resulting from an oncogenic chromosomal translocation inhibits lymphoma dissemination and decreases the risk of relapse.
  • [MeSH-major] Autoantibodies / immunology. Lymphoma, Large-Cell, Anaplastic / immunology. Lymphoma, Large-Cell, Anaplastic / pathology. Neoplasm Recurrence, Local / immunology. Protein-Tyrosine Kinases / immunology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20185586.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Autoantigens; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


53. Weinberg OK, Seo K, Arber DA: Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary? Hum Pathol; 2008 Sep;39(9):1331-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary?
  • The frequency of bone marrow involvement in anaplastic large cell lymphoma has been reported with great variation.
  • A prior study found that anaplastic large cell lymphoma involvement of bone marrow was often not evident on routine stains and advocated using immunohistochemical studies.
  • We evaluated 70 bone marrow biopsies from 41 patients with anaplastic large cell lymphoma and found 10 morphologically involved cases (14% of all biopsies, 22% of all patients).
  • In most cases (9/10 biopsies), the involvement of the bone marrow by anaplastic large cell lymphoma was massive and, thus, was evident on the hematoxylin and eosin section.
  • To determine if the hematoxylin and eosin evaluation missed bone marrow involvement, we used a panel of antibodies including CD30, ALK-1, epithelial membrane antigen, and granzyme.
  • Only the 10 morphologically involved cases showed anaplastic large cell lymphoma cells with distinct CD30 expression.
  • Other stains highlighted only a subset of the CD30-positive cases.
  • Overall, marrow involvement in anaplastic large cell lymphoma was relatively uncommon, and when present, it was identified on hematoxylin and eosin sections.
  • [MeSH-major] Bone Marrow / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adult. Aged, 80 and over. Antigens, CD30 / immunology. Child. Child, Preschool. Clone Cells / pathology. Eosine Yellowish-(YS). Female. Hematoxylin. Humans. Immunohistochemistry. Male. Middle Aged. Protein-Tyrosine Kinases / analysis. Receptor Protein-Tyrosine Kinases. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HEMATOXYLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602674.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


54. Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK, Lam CC, Leung AY, Tse E, Yau CC, Liang R, Kwong YL: Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol; 2005 Feb;16(2):206-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years.
  • BACKGROUND: Data on mature T-cell and natural killer (NK)-cell lymphomas diagnosed with the World Health Organization (WHO) classification scheme are scarce.
  • METHODS: Consecutive T-cell and NK-cell lymphomas classified according to the WHO scheme within 10 years in a Chinese population were reviewed.
  • RESULTS: There were 148 cases, constituting 16.6% (T-cell, n=90, 10.1%, NK-cell, n=58, 6.5%) of all non-Hodgkin lymphomas in this period.
  • There was a male predominance (male:female = 2.5), young age at diagnosis (median age 50 years, range 8-86) and frequent extranodal presentation.
  • Commonest T-cell lymphomas included anaplastic large cell lymphoma (ALCL, n=25, median age 35 years, nodal 60%, stage I/II 60%), peripheral T-cell lymphoma, unspecified (PTCL, n=24, median age 54 years, nodal 42%, stage I/II 42%), and angioimmunoblastic T-cell lymphoma (AILT, n=19, median age 67 years, nodal 95%, stage I/II 26%).
  • Overall frequencies of T-cell lymphomas were comparable to Western patients.
  • AILT, PTCL and ALCL were aggressive with a poor outcome.
  • NK-cell lymphomas were predominantly extranodal (96%) and aggressive, with a frequency much higher than Western patients.
  • CONCLUSIONS: The apparent high prevalence of T-cell and NK-cell lymphomas in the Chinese was due to more frequent NK-cell but not T-cell lymphomas.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668271.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


55. Wilkins S, Millar M, Hemsworth S, Johnson G, Warwick S, Pizer B: Vibrio harveyi sepsis in a child with cancer. Pediatr Blood Cancer; 2008 Apr;50(4):891-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Catheterization, Central Venous / adverse effects. Lymphoma, Large-Cell, Anaplastic / therapy. Seawater / adverse effects. Sepsis / microbiology. Vibrio Infections / physiopathology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Humans. Male. Stem Cell Transplantation. Swimming

  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 17957758.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


56. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M, Choi YL, Niki T, Mano H, Ishikawa Y: EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol; 2008 Jan;3(1):13-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Very recently, we have found a novel fusion product between the echinoderm microtubule-associated protein-like4 (EML4) and the anaplastic lymphoma kinase (ALK) in non-small cell lung cancers (NSCLCs).
  • Herein, we present results of a first large scale study of EML4-ALK fusion in lung cancers.
  • METHODS: Using reverse transcription-polymerase chain reaction for EML4-ALK fusion mRNA, we investigated 149 lung adenocarcinomas, 48 squamous cell carcinomas, 3 large-cell neuroendocrine carcinomas, and 21 small-cell carcinomas.
  • For EML4-ALK-positive cancers, we further investigated the presence of ALK fusion proteins by immunohistochemistry.
  • In all the fusion-positive cases, ALK fusion protein could be detected in the cytoplasm immunohistochemically.
  • Histologically, both variant 1 cases were mixed type adenocarcinomas, showing papillary with bronchioloalveolar components.
  • None of the five fusion-positive cases demonstrated any mutations of EGFR or KRAS, pointing to a mutually exclusive relationship (p = 0.014).
  • CONCLUSIONS: In the present first investigation of EML4-ALK fusion in a large study of lung cancers (5/221), we found an interesting histotype-genotype relationship.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Oncogene Proteins, Fusion / genetics
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma, Neuroendocrine / pathology. Carcinoma, Squamous Cell / pathology. Cell Cycle Proteins / genetics. Chromosome Inversion. Chromosomes, Human, Pair 2. DNA Mutational Analysis. Female. Humans. Immunohistochemistry. Male. Microtubule-Associated Proteins / genetics. Protein-Tyrosine Kinases / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / metabolism. Receptor Protein-Tyrosine Kinases. Reverse Transcriptase Polymerase Chain Reaction. Serine Endopeptidases / genetics. Survival Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166835.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / EML4-ALK fusion protein, human; 0 / Microtubule-Associated Proteins; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 3.4.21.- / EML4 protein, human; EC 3.4.21.- / Serine Endopeptidases
  •  go-up   go-down


57. Gualco G, Chioato L, Weiss LM, Harrington WJ Jr, Bacchi CE: Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children. Am J Clin Pathol; 2009 Jul;132(1):28-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of human T-cell lymphotropic virus in CD25+ anaplastic large cell lymphoma in children.
  • Anaplastic large cell lymphoma (ALCL) is recognized as 2 distinct diseases: anaplastic lymphoma kinase (ALK)+ ALCL and ALK- ALCL.
  • ALK+ ALCL occurs in younger patients and has a better prognosis.
  • Human T-cell lymphotropic virus (HTLV-1) is linked to the development of adult T-cell leukemia/lymphoma (ATLL), which frequently expresses CD25.
  • CD25 is significantly expressed in childhood ALCL.
  • Some cases of adult HTLV-1-related lymphomas have characteristics of ALCL but are considered CD30+ ATLL subtypes.
  • We analyzed 33 cases of pediatric ALCL, CD25+ and CD25-, for proviral HTLV-1 DNA.
  • All cases corresponded to the common histologic ALCL type and were CD30+ in virtually all neoplastic cells.
  • ALK expression was observed in 31 (94%) of 33 cases; CD25 was positive in 27 (82%), including 1 ALK- ALCL case.
  • There was a strong positive correlation between ALK and CD25 expression.
  • ALCL in children has no relationship with HTLV-1; the frequent CD25 expression must be explained by a mechanism different from that in ATLL.

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatrics. 2003 Aug;112(2):e136-42 [12897319.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5587-94 [15328201.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Leukemia. 1994 Mar;8(3):507-9 [8127156.001]
  • [Cites] Hum Pathol. 1995 Jun;26(6):614-9 [7774890.001]
  • [Cites] Mod Pathol. 1996 Jan;9(1):63-7 [8821959.001]
  • [Cites] Histol Histopathol. 1997 Jul;12(3):595-601 [9225139.001]
  • [Cites] Am J Pathol. 1998 Mar;152(3):683-9 [9502410.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Hum Pathol. 2008 Oct;39(10):1505-10 [18620733.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 May 1;21(1):65-71 [10235516.001]
  • [Cites] Blood. 1999 May 1;93(9):3088-95 [10216106.001]
  • [Cites] Oncogene. 2005 Jul 7;24(29):4624-33 [15735688.001]
  • [Cites] J Virol. 2005 Sep;79(18):11925-34 [16140768.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):575-83 [16410787.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):690-2 [16410788.001]
  • [Cites] Haematologica. 2006 May;91(5):596-604 [16670065.001]
  • [Cites] J Pediatr (Rio J). 2006 Nov-Dec;82(6):411-20 [17171202.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):707-22 [17511113.001]
  • [Cites] Oncogene. 2007 May 28;26(25):3699-703 [17530023.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2259-67 [17519389.001]
  • [Cites] Am J Clin Pathol. 2007 Nov;128(5):875-82 [17951212.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2007;:285-96 [18024642.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1560-6 [17957029.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):784-7 [18022899.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1830-5 [11920547.001]
  • [Cites] Am J Hematol. 2001 Jul;67(3):172-8 [11391714.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Mar;16(1):117-33 [12670470.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):823-35 [12131150.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3355-7 [15205267.001]
  • (PMID = 19864230.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA112217-03; United States / NCI NIH HHS / CA / CA121935-03; United States / NCI NIH HHS / CA / R01 CA112217-03; United States / NCI NIH HHS / CA / R01 CA082274-08; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / R01 CA121935-03; United States / NCI NIH HHS / CA / R01 CA121935
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / IL2RA protein, human; 0 / Interleukin-2 Receptor alpha Subunit; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ NIHMS125676; NLM/ PMC2771325
  •  go-up   go-down


58. Karube K, Aoki R, Nomura Y, Yamamoto K, Shimizu K, Yoshida S, Komatani H, Sugita Y, Ohshima K: Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. Pathol Int; 2008 Feb;58(2):89-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases.
  • Although various CD markers have been analyzed in T-cell and natural killer (NK)-cell lymphomas, the sensitivity and specificity of these phenotypic features have not been satisfactorily characterized.
  • Flow cytometry (FCM) was used to determine the phenotypic pattern of 490 T/NK-cell lymphomas with the aid of a set of surface antigens (CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD25, CD30, CD34, and CD56).
  • In data obtained from 319 patients, CD10 expression was detected in 57% of angioimmunoblastic T-cell lymphomas, CD30 in 93% of anaplastic large cell lymphomas, CD34 in 50% of lymphoblastic lymphomas, and CD56 in 100% of extranodal NK/T-cell lymphomas nasal type.
  • A total of 92% of adult T-cell leukemia/lymphomas (ATLL) had expression of CD25 and downregulation of CD7.
  • Of special interest is that 92 ATLL (50%) were CD4+CD7-CD25+ phenotype while only four peripheral T-cell lymphoma unspecified (9%) and one (9%) cutaneous T-cell lymphoma had this phenotype.
  • Phenotypic analysis using FCM was thus found to be useful for differential diagnosis of T-cell and NK-cell lymphomas.
  • [MeSH-major] Flow Cytometry / methods. Killer Cells, Natural / pathology. Lymphoma, T-Cell / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Antigens, CD / analysis. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunophenotyping. Lymph Nodes / immunology. Lymph Nodes / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18199158.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


59. Harbell JW, Dunn TB, Fauda M, John DG, Goldenberg AS, Teperman LW: Transmission of anaplastic large cell lymphoma via organ donation after cardiac death. Am J Transplant; 2008 Jan;8(1):238-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transmission of anaplastic large cell lymphoma via organ donation after cardiac death.
  • We present a case of anaplastic T-cell lymphoma transmitted to four recipients of solid organ transplants from a DCD donor suspected of having bacterial meningitis.
  • On brain biopsy, the donor was found to have anaplastic central nervous system T-cell lymphoma, and the recipient of the donor's pancreas, liver and kidneys were found to have involvement of T-cell lymphoma.
  • In cases of lymphoma transmission, excision of the graft may be the only chance at long-term survival.
  • [MeSH-major] Death. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / etiology. Organ Transplantation / adverse effects. Tissue Donors


60. Sonnen R, Schmidt WP, Müller-Hermelink HK, Schmitz N: The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. Br J Haematol; 2005 May;129(3):366-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas.
  • The World Health Organization (WHO) lymphoma classification recognises anaplastic large cell lymphoma (ALCL), angioimmunoblastic lymphoma (AIL) and peripheral T-cell lymphoma, unspecified (PTCU) as nodal mature T-cell lymphomas.
  • A retrospective analysis on 125 patients with ALCL, AIL or PTCU was performed to evaluate outcome parameters, taking into account histological subtype and the International Prognostic Index (IPI).
  • Five-year OS was 61% for ALCL, 45% for PTCU and 28% for AIL.
  • To a large extent, the IPI score explains the differences in survival between histological subtypes of nodal mature T-cell lymphomas.
  • The IPI may therefore be used for risk stratification in clinical trials to identify patients who would benefit most from new treatment strategies, such as high-dose chemotherapy followed by stem cell or bone marrow transplantation.
  • [MeSH-major] Lymphoma, T-Cell / diagnosis. Severity of Illness Index
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bone Marrow Transplantation. Cause of Death. Epidemiologic Methods. Female. Hematopoietic Stem Cell Transplantation. Humans. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell, Peripheral / diagnosis. Lymphoma, T-Cell, Peripheral / therapy. Male. Middle Aged. Neoplasms, Second Primary. Prognosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842660.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Staber PB, Vesely P, Haq N, Ott RG, Funato K, Bambach I, Fuchs C, Schauer S, Linkesch W, Hrzenjak A, Dirks WG, Sexl V, Bergler H, Kadin ME, Sternberg DW, Kenner L, Hoefler G: The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling. Blood; 2007 Nov 1;110(9):3374-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The oncoprotein NPM-ALK of anaplastic large-cell lymphoma induces JUNB transcription via ERK1/2 and JunB translation via mTOR signaling.
  • Anaplastic large cell lymphomas (ALCLs) are highly proliferating tumors that commonly express the AP-1 transcription factor JunB.
  • ALK fusions occur in approximately 50% of ALCLs, and among these, 80% have the t(2;5) translocation with NPM-ALK expression.
  • We report greater activity of JunB in NPM-ALK-positive than in NPM-ALK-negative ALCLs.
  • Specific knockdown of JUNB mRNA using small interfering RNA and small hairpin RNA in NPM-ALK-expressing cells decreases cellular proliferation as evidenced by a reduced cell count in the G2/M phase of the cell cycle.
  • Both NPM-ALK-positive and -negative ALCL tumors demonstrate active ERK1/2 signaling.
  • In contrast to NPM-ALK-negative ALCL, the mTOR pathway is active in NPM-ALK-positive lymphomas.
  • Pharmacological inhibition of mTOR in NPM-ALK-positive cells down-regulates JunB protein levels by shifting JUNB mRNA translation from large polysomes to monosomes and ribonucleic particles (RNPs), and decreases cellular proliferation.
  • Thus, JunB is a critical target of mTOR and is translationally regulated in NPM-ALK-positive lymphomas.
  • In conjunction with NPM-ALK, JunB enhances cell cycle progression and may therefore represent a therapeutic target.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / genetics. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / metabolism. Protein Kinases / physiology. Protein-Tyrosine Kinases / physiology. Proto-Oncogene Proteins c-jun / genetics. Proto-Oncogene Proteins c-jun / metabolism. Transcriptional Activation


62. Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, Kadin ME, Abraham LJ, Watanabe T, Horie R: JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res; 2005 Sep 1;65(17):7628-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma.
  • High expression of CD30 and JunB is characteristic of tumor cells in anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL).
  • Possible interactions of CD30 and JunB were examined in this study.
  • We found that the CD30 promoter in tumor cells of both nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK)-positive and NPM-ALK-negative ALCL and HL is regulated by a constitutively active CD30-extracellular signal-regulated kinase (ERK) 1/2 mitogen-activated protein kinase (MAPK).
  • Phosphorylation of ERK1/2 MAPK was confirmed in nuclei of tumor cells in both ALCL and HL.
  • CD30-ERK1/2 MAPK signals induce JunB expression, which maintains high activity of the CD30 promoter.
  • JunB induction seems to be largely independent of nuclear factor kappaB in ALCL and HL.
  • These results show a common mechanism of CD30 overexpression in ALCL and HL, although the outcome of CD30 signaling differs between NPM-ALK-positive ALCL and NPM-ALK-negative ALCL, cutaneous ALCL, and HL as we recently reported.
  • [MeSH-major] Antigens, CD30 / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Hodgkin Disease / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. MAP Kinase Signaling System / physiology. Proto-Oncogene Proteins c-jun / biosynthesis. Reed-Sternberg Cells / metabolism
  • [MeSH-minor] Cell Line, Tumor. Humans. K562 Cells. NF-kappa B / metabolism. Promoter Regions, Genetic. Protein Binding. Transcription Factor AP-1 / metabolism


63. Patel P, Godwin J, Velankar M, Alkan S: Nodal ALK positive anaplastic large cell lymphoma of the axilla with spontaneous regression. Leuk Lymphoma; 2007 Jun;48(6):1250-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodal ALK positive anaplastic large cell lymphoma of the axilla with spontaneous regression.
  • [MeSH-major] Axilla. Lymph Nodes / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasm Regression, Spontaneous. Protein-Tyrosine Kinases / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577798.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


64. Wang XQ, Sino-US Leukemia Cooperative Group of Shanghai: [Cytogenetic study on 155 cases of non-Hodgkin' s lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2006 Oct;27(10):656-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetic study on 155 cases of non-Hodgkin' s lymphoma].
  • OBJECTIVE: To investigate the relationship between histopathological subtype of non-Hodgkin' s lymphoma(NHL) and chromosomal abnormalities, and compare the difference of chromosomal abnormalities between China and the West.
  • RESULTS: Diffuse large B-cell lymphoma( DLBCL) constituted 38.1% of the cases followed by follicular lymphoma(FL) 17.4% , small lymphocytic lymphoma( SLL) 10.3% , peripheral T-cell lymphoma ( PTCL) ( unspecified) 8.4%, and angioimmunoblastic lymphoma 7.1%.
  • The incidence of chromosomal abnormalities among FL, SLL, DLBCL, anaplastic large cell lymphoma (ALCL) and precursor T-cell lymphoblastic lymphoma (TLBL) was 96.3% , 87.5% , 86.4%, 83.3% and 83.3%, respectively.
  • The most frequent structural abnormalities in DLBCL involved chromosomes 3, 6, 14 and 1, with had high frequencies of 3q27 (41.2%) and 6q21, 6q23, 6q25 involvement (23.5%).
  • The positive rate of IgH rearrangement was 40.
  • Normal karyotype was observed in 8/11 cases with angioimmunoblastic T-cell lymphoma patients.
  • The incidence of chromosomal abnormalities in angioimmunoblastic T-cell lymphoma was lower than that in the West.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adult. Chromosome Structures. Cytogenetic Analysis. Female. Humans. In Situ Hybridization, Fluorescence. Lymphoma, Large B-Cell, Diffuse / classification. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Male

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343195.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


65. Duvic M, Talpur R, Wen S, Kurzrock R, David CL, Apisarnthanarax N: Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma; 2006 Jul;7(1):51-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
  • PURPOSE: The purpose of this study was to investigate safety and efficacy of gemcitabine monotherapy for cutaneous T-cell lymphoma (CTCL).
  • RESULTS: Two patients with CD30+ anaplastic large T-cell lymphoma and 31 with mycosis fungoides (stage IB [T2, n = 2], stage IIA [T2, n = 1], stage IIB [T3, n = 13], stage IVA [T3 N3, n = 3; T4b2, n = 2; T4b2 N3, n = 2], and stage IVB [T4b2 N1, n = 6; T4 N3b2 M1, n = 1; T3 N3 M1, n = 1]) had received a median of 5 previous therapies (range, 1-13 therapies).
  • Myelosuppression (n = 14; grade 3, n = 8), hemolytic uremic syndrome (in 2 elderly patients with Sezary syndrome), pulmonary embolism (n = 2), and 1 episode each of congestive heart failure, acute myocardial infarction, and stable angina were observed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Deoxycytidine / analogs & derivatives. Lymphoma, T-Cell, Cutaneous / drug therapy. Sezary Syndrome / drug therapy. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879770.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672-22; United States / NCI NIH HHS / CA / K24 CA 86815
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Interleukin-2; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


66. Niitsu N, Kohri M, Hayama M, Tamaru J, Miura I: ALK-positive anaplastic large cell lymphoma with dic(2;4)(p23;q33). Leuk Res; 2009 Jun;33(6):e23-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive anaplastic large cell lymphoma with dic(2;4)(p23;q33).
  • [MeSH-major] Chromosomes, Human, Pair 2. Chromosomes, Human, Pair 4. Lymphoma, Large-Cell, Anaplastic / genetics. Protein-Tyrosine Kinases / metabolism. Translocation, Genetic

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036440.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


67. d'Amore ES, Menin A, Bonoldi E, Bevilacqua P, Cazzavillan S, Donofrio V, Gambini C, Forni M, Gentile A, Magro G, Boldrini R, Pillon M, Rosolen A, Alaggio R: Anaplastic large cell lymphomas: a study of 75 pediatric patients. Pediatr Dev Pathol; 2007 May-Jun;10(3):181-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphomas: a study of 75 pediatric patients.
  • In this article, we describe the morphologic and immunophenotypic features of 75 cases of pediatric anaplastic large cell lymphoma (ALCL).
  • According to the World Health Organization classification, 49 cases were common subtype ALCL, and respectively, 3, 6, and 17 cases were small cell, lymphohistiocytic, or mixed histologic variants.
  • Anaplastic lymphoma kinase positivity was detected in 90.7% of the tumors and, using a panel of 9 T-cell surface markers, 88% could be assigned to the T-cell lineage.
  • A molecular analysis for the T-cell receptor gamma (TCR- gamma) and the heavy chain of the immunoglobulin H rearrangements was performed on 6/9 ALCLs with a null immunophenotype, and a TCR clonal pattern was detected in 5/6 cases.
  • Clusterin, CD83, and Pax5, respectively, expressed in 91.3%, 1.7%, and 0% of the ALCLs, were useful biomarkers for the differential diagnosis with Hodgkin's lymphomas.
  • [MeSH-major] Antigens, CD / immunology. Antigens, CD56 / immunology. B-Cell-Specific Activator Protein / immunology. Biomarkers, Tumor / immunology. Clusterin / immunology. Immunoglobulins / immunology. Lymphoma, Large B-Cell, Diffuse / immunology. Membrane Glycoproteins / immunology
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Granzymes / immunology. Hodgkin Disease / diagnosis. Hodgkin Disease / immunology. Hodgkin Disease / pathology. Humans. Immunohistochemistry. Immunophenotyping. Lymphocytes, Null / immunology. Lymphocytes, Null / pathology. Lymphoma, Large-Cell, Anaplastic / immunology. Lymphoma, Large-Cell, Anaplastic / pathology. Male. Perforin. Poly(A)-Binding Proteins / immunology. Pore Forming Cytotoxic Proteins / immunology. Receptors, Antigen, T-Cell, gamma-delta / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pediatr Dev Pathol. 2007 May-Jun;10(3):169-71 [17535094.001]
  • (PMID = 17535098.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / B-Cell-Specific Activator Protein; 0 / Biomarkers, Tumor; 0 / CD83 antigen; 0 / CLU protein, human; 0 / Clusterin; 0 / Immunoglobulins; 0 / Membrane Glycoproteins; 0 / PAX5 protein, human; 0 / Poly(A)-Binding Proteins; 0 / Pore Forming Cytotoxic Proteins; 0 / Receptors, Antigen, T-Cell, gamma-delta; 0 / TIA1 protein, human; 126465-35-8 / Perforin; EC 3.4.21.- / Granzymes
  •  go-up   go-down


68. de Jong D, Vasmel WL, de Boer JP, Verhave G, Barbé E, Casparie MK, van Leeuwen FE: Anaplastic large-cell lymphoma in women with breast implants. JAMA; 2008 Nov 5;300(17):2030-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large-cell lymphoma in women with breast implants.
  • CONTEXT: Recently, we identified 2 patients with anaplastic large T-cell lymphoma (ALCL) negative for tyrosine kinase anaplastic lymphoma kinase (ALK-negative) in the fibrous capsule of silicone breast prostheses, placed for cosmetic reasons.
  • Although an increased risk of ALCL in patients with breast prostheses has been speculated, no studies have been conducted so far.
  • OBJECTIVE: To determine whether ALCL risk is associated with breast prostheses.
  • DESIGN: A search for all patients with lymphoma in the breast diagnosed in The Netherlands between 1990 and 2006 was performed through the population-based nationwide pathology database.
  • Conditional logistic regression analysis was performed to estimate the relative risk of ALCL associated with breast prostheses.
  • SETTING AND PATIENTS: Eleven patients with breast ALCL were identified in the registry.
  • For each case patient with ALCL in the breast, we selected 1 to 5 controls with other lymphomas in the breast, matched on age and year of diagnosis.
  • MAIN OUTCOME MEASURE: Association between breast implants and ALCL of the breast.
  • RESULTS: The 11 patients with ALCL of the breast were diagnosed between 1994 and 2006 at a median age of 40 years (range, 24-68 years).
  • In 5 of these patients, bilateral silicone breast prostheses had been placed 1 to 23 years before diagnosis.
  • Lymphoma classes of 35 eligible control patients were 12 diffuse large B-cell lymphomas, including 1 T-cell rich B-cell lymphoma; 5 Burkitt lymphomas; 10 mucosa-associated lymphoid tissue-type lymphoma; 3 follicular lymphomas; 3 peripheral T-cell lymphomas; and 2 indolent B-cell lymphomas, unclassified.
  • One of 35 control patients had a breast implant placed before diagnosis of lymphoma.
  • The odds ratio for ALCL associated with breast prostheses was 18.2 (95% confidence interval, 2.1-156.8).
  • CONCLUSIONS: These preliminary findings suggest an association between silicone breast prostheses and ALCL, although the absolute risk is exceedingly low due to the rare occurrence of ALCL of the breast (11 cases in The Netherlands in 17 years).


69. Watanabe N, Kato H, Murakami J, Shimizu M, Noguchi K, Kamisaki Y, Matsunari I, Seto H: FDG-PET imaging in cutaneous anaplastic large cell lymphoma. Clin Nucl Med; 2006 Sep;31(9):564-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET imaging in cutaneous anaplastic large cell lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921287.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


70. Nagajothi N, Dham SK, Gelfand Y, Sanmugarajah J: Treatment of AIDS-associated anaplastic large-cell lymphoma with dose-adjusted EPOCH chemotherapy. J Natl Med Assoc; 2007 Jul;99(7):799-801
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of AIDS-associated anaplastic large-cell lymphoma with dose-adjusted EPOCH chemotherapy.
  • Anaplastic large-cell lymphoma (ALCL) has rarely been described in patients with acquired immunodeficiency syndrome (AIDS).
  • Reports of treatment of ALCL in the setting of AIDS are rare as well.
  • Dose-adjusted EPOCH (DA-EPOCH; etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) has been shown to be well tolerated and effective in the treatment of AIDS-related aggressive B-cell lymphomas.
  • Treatment of AIDS-associated ALCL with DA-EPOCH has not been reported.
  • This report describes two patients with AIDS-associated ALCL treated with DA-EPOCH chemotherapy.
  • Both patients presented with advanced disease.
  • She had an excellent response with rapid improvement of cutaneous disease and lymphadenopathy starting three days after the first cycle.
  • Our experience suggests that DA-EPOCH is an effective treatment for AIDS-associated ALCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 2005 Aug 16;143(4):265-73 [16103470.001]
  • [Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1954-60 [7655022.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1694-700 [7655001.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):3078-90 [8221575.001]
  • [Cites] Am J Surg Pathol. 1988 Apr;12(4):264-74 [3354752.001]
  • [Cites] Blood. 2000 Dec 1;96(12):3681-95 [11090048.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • [Cites] Ai Zheng. 2004 Aug;23(8):943-6 [15301720.001]
  • (PMID = 17668647.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; EPOCH protocol
  • [Other-IDs] NLM/ PMC2574342
  •  go-up   go-down


71. Parlette EC, Tabor CA: CD30+, large T-cell lymphoma: diagnostic distinction and management. Dermatol Online J; 2006;12(6):8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30+, large T-cell lymphoma: diagnostic distinction and management.
  • Cutaneous T-cell lymphoma (CTCL) has a variable presentation and comprises a broad diagnostic group.
  • Histologic and immunophenotypic confirmation is needed to establish a precise diagnosis.
  • Primary cutaneous, CD-30+, anaplastic, large T-cell lymphoma represents an indolent form of CTCL that often spontaneously involutes.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / diagnosis
  • [MeSH-minor] Aged. Antigens, CD / analysis. Clobetasol / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Immunophenotyping. Remission Induction. Remission, Spontaneous. Thigh

  • Hazardous Substances Data Bank. Clobetasol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083888.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; ADN79D536H / Clobetasol
  •  go-up   go-down


72. van Kester MS, Tensen CP, Vermeer MH, Dijkman R, Mulder AA, Szuhai K, Willemze R, van Doorn R: Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators. J Invest Dermatol; 2010 Feb;130(2):563-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous anaplastic large cell lymphoma and peripheral T-cell lymphoma NOS show distinct chromosomal alterations and differential expression of chemokine receptors and apoptosis regulators.
  • Primary cutaneous anaplastic large cell lymphoma (C-ALCL) has an indolent clinical course and favorable prognosis.
  • On the contrary, primary cutaneous peripheral T-cell lymphoma not otherwise specified (PTL-NOS) shows aggressive clinical behavior.
  • To identify genomic events relevant in the pathogenesis of these cutaneous T-cell lymphomas (CTCLs), we carried out array-based comparative genomic hybridization (CGH) analysis.
  • C-ALCL was characterized by gains on chromosome 7q and 17q and losses on 6q and 13q.
  • We identified minimal common regions harboring candidate oncogenes and tumor suppressor genes in C-ALCL and PTL-NOS.
  • Genes with a role in lymphocyte chemotaxis, apoptosis, and proliferation were overrepresented among genes differentially expressed between these lymphomas.
  • C-ALCL showed higher expression of the skin-homing chemokine receptor genes CCR10 and CCR8, which may explain the lower tendency to disseminate to extracutaneous sites.
  • Furthermore, C-ALCL and PTL-NOS showed aberrant expression of distinct genes implicated in apoptosis and proliferation, such as IRF4/MUM1 and PRKCQ, which may account for differences in clinical aggressiveness.
  • [MeSH-major] Chromosome Aberrations. Gene Expression Regulation, Neoplastic. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, T-Cell, Peripheral / genetics. Lymphoma, T-Cell, Peripheral / metabolism. Skin Neoplasms / genetics. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Chemokines / metabolism. Chromosome Mapping. Female. Genetic Predisposition to Disease. Humans. Lymphocytes / cytology. Male. Middle Aged


73. Yamazaki T, Sawada U, Kura Y, Ito T, Takeuchi J, Hatta Y, Aikawa S, Takei K, Ishizuka H, Saiki M, Uenogawa K: Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study. Acta Haematol; 2006;116(2):90-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of high-risk peripheral T-cell lymphomas other than anaplastic large-cell lymphoma with a dose-intensified CHOP regimen followed by high-dose chemotherapy. A single institution study.
  • We investigated the efficacy of a dose-intensified double-CHOP regimen followed by high-dose chemotherapy with or without peripheral blood stem cell transplantation (PBSCT) in 11 patients with four types of peripheral T-cell lymphoma (PTCL).
  • Three of the 4 patients with unspecified PTCL (PTCLu) achieved complete response (CR); 1 patient relapsed and 1 died of secondary leukemia after consolidation therapy.
  • All angioimmunoblastic T-cell lymphoma (AILT) and subcutaneous panniculitis-like T-cell lymphoma (SPTCL) patients achieved CR; 5 of 6 have remained disease free for more than 3 years.
  • The patient with hepatosplenic lymphoma did not achieve CR even after PBSCT and underwent allogenic bone marrow transplantation (allo-BMT).
  • However, allo-BMT should be considered for high-risk of PTCLu and hepatosplenic T-cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / drug therapy


74. Shi X, Franko B, Frantz C, Amin HM, Lai R: JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells. Br J Haematol; 2006 Oct;135(1):26-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JSI-124 (cucurbitacin I) inhibits Janus kinase-3/signal transducer and activator of transcription-3 signalling, downregulates nucleophosmin-anaplastic lymphoma kinase (ALK), and induces apoptosis in ALK-positive anaplastic large cell lymphoma cells.
  • As STAT3 activation is pathogenetically important in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL), we investigated whether JSI-124 can mediate significant inhibitory effects in this cell type.
  • In two ALK+ ALCL cell lines (Karpas 299 and SU-DHL-1), JSI-124 significantly reduced the number of viable cells to 50% of that of negative controls at a dose of 5-10 micromol/l at 24 h and 1-1.25 micromol/l at 48 h.
  • Our data support that JSI-124 is a potentially useful therapeutic agent for ALK+ ALCL.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / antagonists & inhibitors. Triterpenes / pharmacology


75. Sharma PK, He M, Jurayj J, Gou DM, Lombardy R, Romanczyk LJ Jr, Schroeter H: Enantioselctive syntheses of sulfur analogues of flavan-3-Ols. Molecules; 2010 Aug;15(8):5595-619
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The key steps were: (a) Pd(0) catalyzed introduction of -S t-butyl group, (b) Sharpless enantioselective dihydroxylation of the alkene, (c) acid catalyzed ring closure to produce the thiopyran ring, and (d) removal of benzyl groups using N,N-dimethylaniline and AlCl(3).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20714315.001).
  • [ISSN] 1420-3049
  • [Journal-full-title] Molecules (Basel, Switzerland)
  • [ISO-abbreviation] Molecules
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Flavonoids; 0 / Sulfur Compounds; 0 / flavan-3-ol
  •  go-up   go-down


76. Akimzhanov A, Krenacs L, Schlegel T, Klein-Hessling S, Bagdi E, Stelkovics E, Kondo E, Chuvpilo S, Wilke P, Avots A, Gattenlöhner S, Müller-Hermelink HK, Palmetshofer A, Serfling E: Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATC1) promoter in human lymphomas with defects in immunoreceptor signaling. Am J Pathol; 2008 Jan;172(1):215-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic changes and suppression of the nuclear factor of activated T cell 1 (NFATC1) promoter in human lymphomas with defects in immunoreceptor signaling.
  • The nuclear factor of activated T cell 1 (Nfatc1) locus is a common insertion site for murine tumorigenic retroviruses, suggesting a role of transcription factor NFATc1 in lymphomagenesis.
  • Although NFATc1 is expressed in most human primary lymphocytes and mature human T- and B-cell neoplasms, we show by histochemical stainings that NFATc1 expression is suppressed in anaplastic large cell lymphomas and classical Hodgkin's lymphomas (HLs).
  • In HL cell lines, NFATc1 silencing correlated with a decrease in histone H3 acetylation, H3-K4 trimethylation, and Sp1 factor binding but with an increase in HP1 binding to the NFATC1 P1 promoter.
  • Together with DNA hypermethylation of the NFATC1 P1 promoter, which we detected in all anaplastic large cell lymphoma and many HL lines, these observations reflect typical signs of transcriptional silencing.
  • In several lymphoma lines, methylation of NFATC1 promoter DNA resulted in a "window of hypomethylation," which is flanked by Sp1-binding sites.
  • [MeSH-minor] Animals. DNA Methylation. Histones / metabolism. Hodgkin Disease / metabolism. Humans. Immunohistochemistry / methods. Mice. Signal Transduction. Sp1 Transcription Factor / metabolism. Transcription, Genetic

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2000 Mar;12(3):293-300 [10755616.001]
  • [Cites] Toxicol In Vitro. 2007 Dec;21(8):1402-8 [17590309.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1172-9 [11222358.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2476-89 [11402342.001]
  • [Cites] Cancer Res. 2001 Jul 15;61(14):5558-61 [11454707.001]
  • [Cites] Science. 2001 Aug 10;293(5532):1074-80 [11498575.001]
  • [Cites] Hum Mol Genet. 2001 Dec 15;10(26):3001-7 [11751682.001]
  • [Cites] Eur J Biochem. 2002 Feb;269(4):1162-70 [11856352.001]
  • [Cites] Science. 2002 Mar 8;295(5561):1901-4 [11884757.001]
  • [Cites] Nat Cell Biol. 2002 Jul;4(7):540-4 [12080349.001]
  • [Cites] Immunity. 2002 Jun;16(6):881-95 [12121669.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5427-40 [12154405.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1071-81 [12453415.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1505-12 [12393731.001]
  • [Cites] Eur J Immunol. 2003 Jan;33(1):1-11 [12594826.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):17246-54 [12598522.001]
  • [Cites] Genes Dev. 2003 Sep 15;17(18):2205-32 [12975316.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D523-7 [14681473.001]
  • [Cites] J Immunol. 2004 Apr 15;172(8):4812-20 [15067058.001]
  • [Cites] Novartis Found Symp. 2004;259:22-37; discussion 37-47, 163-9 [15171245.001]
  • [Cites] Genes Dev. 2004 Jun 1;18(11):1251-62 [15145825.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Aug;83(16):5889-93 [3461465.001]
  • [Cites] Genes Dev. 1988 Sep;2(9):1127-35 [3056778.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Nature. 1994 Jun 9;369(6480):497-502 [8202141.001]
  • [Cites] EMBO J. 1994 Aug 15;13(16):3843-51 [8070411.001]
  • [Cites] Nature. 1994 Sep 29;371(6496):435-8 [8090226.001]
  • [Cites] Genes Dev. 1994 Oct 1;8(19):2282-92 [7958895.001]
  • [Cites] Br J Cancer. 1997;76(9):1150-6 [9365162.001]
  • [Cites] J Biol Chem. 1997 Dec 12;272(50):31427-34 [9395475.001]
  • [Cites] Nucleic Acids Res. 1999 Jun 1;27(11):2291-8 [10325416.001]
  • [Cites] J Immunol. 1999 Jun 15;162(12):7294-301 [10358178.001]
  • [Cites] Eur J Immunol. 1999 Sep;29(9):3017-27 [10508276.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3326-34 [15284123.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3358-60 [15297316.001]
  • [Cites] Br J Haematol. 2005 Feb;128(3):333-42 [15667535.001]
  • [Cites] Braz J Med Biol Res. 2005 Mar;38(3):335-44 [15761612.001]
  • [Cites] Leukemia. 2005 May;19(5):856-61 [15744341.001]
  • [Cites] Nat Rev Immunol. 2005 Jun;5(6):472-84 [15928679.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 2004;69:209-18 [16117651.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3546-52 [16051745.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3940-7 [16099873.001]
  • [Cites] Mol Cell. 2005 Nov 23;20(4):539-50 [16307918.001]
  • [Cites] Cell Calcium. 2006 Apr;39(4):313-24 [16445977.001]
  • [Cites] J Biol Chem. 2006 May 5;281(18):12210-7 [16505480.001]
  • [Cites] EMBO J. 2006 Aug 9;25(15):3714-24 [16874304.001]
  • [Cites] Trends Immunol. 2006 Oct;27(10):461-9 [16931157.001]
  • [Cites] J Immunol. 2006 Oct 1;177(7):4567-76 [16982894.001]
  • [Cites] Am J Pathol. 1999 Nov;155(5):1767-72 [10550333.001]
  • [Cites] Eur J Immunol. 1999 Nov;29(11):3456-65 [10556800.001]
  • [Cites] J Exp Med. 2000 Jan 3;191(1):9-22 [10620601.001]
  • [Cites] J Natl Cancer Inst. 2000 Apr 5;92(7):564-9 [10749912.001]
  • [Cites] Nat Med. 2007 Jun;13(6):736-41 [17515895.001]
  • [Cites] Sci STKE. 2007 Aug 25;2007(398):pe42 [17684296.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 20;1498(1):1-18 [11042346.001]
  • (PMID = 18156209.001).
  • [ISSN] 0002-9440
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Histones; 0 / NFATC Transcription Factors; 0 / NFATC1 protein, human; 0 / Nfatc1 protein, mouse; 0 / Sp1 Transcription Factor
  • [Other-IDs] NLM/ PMC2189623
  •  go-up   go-down


77. Lund CL, Schachner JA, Burgess IJ, Quail JW, Schatte G, Müller J: Synthesis and characterization of aluminum- and gallium-bridged [1.1]chromarenophanes and [1.1]molybdarenophanes. Inorg Chem; 2008 Jul 7;47(13):5992-6000
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A salt-metathesis reaction of [2-(Me 2NCH 2)C 6H 4]AlCl 2 with freshly prepared [Cr(LiC 6H 5) 2].TMEDA (TMEDA = N, N, N', N'-tetramethylethylenediamine) resulted in the dialumina[1.1]chromarenophane [{2-(Me 2NCH 2)C 6H 4}Al(eta (6)-C 6H 5) 2Cr] 2 ( 2a).
  • Salt-metathesis reactions of 3a and 3b, respectively, with freshly prepared [M(LiC 6H 5) 2].TMEDA (M = Cr, Mo) resulted in four new [1.1]metallarenophanes of the general type [{5- tBu-2-(Me 2NCH 2)C 6H 3}E(eta (6)-C 6H 5) 2M] 2 [E = Al, M = Cr ( 4a); E = Ga, M = Cr ( 4b); E = Al, M = Mo ( 5a); E = Ga, M = Mo ( 5b)].

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533628.001).
  • [ISSN] 1520-510X
  • [Journal-full-title] Inorganic chemistry
  • [ISO-abbreviation] Inorg Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Erdogan-Orhan I, Sever-Yılmaz B, Altun ML, Saltan G: Radical quenching activity, ferric-reducing antioxidant power, and ferrous ion-chelating capacity of 16 Ballota species and their total phenol and flavonoid contents. J Med Food; 2010 Dec;13(6):1537-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total phenol and flavonoid contents of the extracts were determined by Folin-Ciocalteau and AlCl(3) reagents, respectively.
  • The extracts showed insignificant quenching activity against DPPH radical, but they had moderate antioxidant activity (0.597 ± 0.03 to 1.342 ± 0.01) in the ferric-reducing test compared to chlorogenic acid (the reference compound) (3.618 ± 0.01).

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21091260.001).
  • [ISSN] 1557-7600
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Diterpenes; 0 / Flavonoids; 0 / Food Preservatives; 0 / Free Radical Scavengers; 0 / Iron Chelating Agents; 0 / Phenols; 0 / Plant Extracts; 0 / Solvents; 0 / hispanolone
  •  go-up   go-down


79. Tripathi S, Mahdi AA, Nawab A, Chander R, Hasan M, Siddiqui MS, Mahdi F, Mitra K, Bajpai VK: Influence of age on aluminum induced lipid peroxidation and neurolipofuscin in frontal cortex of rat brain: a behavioral, biochemical and ultrastructural study. Brain Res; 2009 Feb 9;1253:107-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The markers of oxidative stress, e.g. lipid peroxides and endogenous antioxidants as well as metals (Al, Fe, Cu, Zn and Se) were measured in the brain frontal cortex of young and aged rats fed with AlCl(3) (100 mg/kg b.w.) for 90 days and normal saline treated controls.
  • On the basis of the results of the present study, we conclude that Al may be linked with neurolipofuscinogenesis and alteration in neurobehavioral activity and these changes may be responsible for the development of age related disorders, such as Alzheimer's disease.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19073157.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Antioxidants; 0 / Chlorides; 0 / Lipid Peroxides; 0 / Lipofuscin; 0 / Metals, Heavy; 3CYT62D3GA / aluminum chloride; H6241UJ22B / Selenium
  •  go-up   go-down


80. Hacıhanefioğlu A, Tarkun P, Gonullu E, Vardar O: Lymphomas of Waldeyer's ring: Clinical features, management and prognosis of eleven adult patients. Turk J Haematol; 2008 Jun 5;25(2):75-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphomas of Waldeyer's ring: Clinical features, management and prognosis of eleven adult patients.
  • Lymphoma is the second most common neoplasm of the head and neck after squamous carcinoma.
  • The majority of lym¬phomas involving the head and neck are non-hodgkin's lymphomas.
  • Hodgkin's lymphoma is rare in Waldeyer's ring.
  • Between 1999 and 2006, the medical records and pathology data of all newly diagnosed, previously untreated adult patients with Waldeyer's ring lymphomas were retrospectively reviewed.
  • Approximately one month after the end of the scheduled initial management, patients were restaged for evidence of residual disease with physical examination, laboratory profiles and relevant radiologic studies.
  • Complete remission was achieved in 6 patients and partial remission in 3 patients; 1 patient did not achieve remission and 1 patient with anaplastic large cell lymphoma died.
  • The progression of patients with lymphoma is closely associated with the diagnosis, stage and histologic grade of the disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27264443.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


81. Kim SK, Kim IS, Jun JB: Anaplastic large cell lymphoma in a patient with rheumatoid arthritis taking low dose methotrexate. Rheumatol Int; 2006 Jun;26(8):775-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma in a patient with rheumatoid arthritis taking low dose methotrexate.
  • [MeSH-major] Antirheumatic Agents / therapeutic use. Lymphoma, Large-Cell, Anaplastic / immunology. Lymphoma, Large-Cell, Anaplastic / pathology. Methotrexate / adverse effects. Methotrexate / therapeutic use


82. Campo E, Chott A, Kinney MC, Leoncini L, Meijer CJ, Papadimitriou CS, Piris MA, Stein H, Swerdlow SH: Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology; 2006 Apr;48(5):481-504
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece.
  • Classification and proper treatment of extranodal lymphoma is hindered by the diversity of lymphoma types and the relative rarity of many of these tumour types.
  • In order to review controversial issues in extranodal lymphoma diagnosis, a joint Workshop of the European Haematopathology Association (EAHP) and the Society for Hematopathology (SH) was held, where 99 selected cases were reviewed and discussed.
  • This Workshop summary is focused on the most controversial aspect of cutaneous B-cell lymphoma, other extranodal B-cell lymphomas, plasmablastic lymphoma and anaplastic large-cell lymphoma in extranodal sites, and makes practical recommendations about diagnosis and therapeutic approaches.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Diagnosis, Differential. Gastrointestinal Tract / pathology. Humans. Lung / pathology. Salivary Glands / pathology. Skin / pathology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Jun;18(6):806-15 [15578069.001]
  • [Cites] Hum Pathol. 2005 May;36(5):494-504 [15948116.001]
  • [Cites] Immunol Res. 2005;32(1-3):75-83 [16106060.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2491-7 [15947086.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):52-8 [10564586.001]
  • [Cites] Thyroid. 1999 Dec;9(12):1273-80 [10646671.001]
  • [Cites] Blood. 2000 Feb 1;95(3):802-6 [10648389.001]
  • [Cites] Mod Pathol. 2000 Jan;13(1):19-28 [10658906.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1406-12 [10666218.001]
  • [Cites] J Clin Pathol. 1999 Nov;52(11):849-50 [10690178.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):623-39 [10800981.001]
  • [Cites] Am J Surg Pathol. 2000 May;24(5):688-93 [10800987.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3653-61 [10845893.001]
  • [Cites] Hum Pathol. 2004 May;35(5):632-5 [15138941.001]
  • [Cites] Am J Clin Pathol. 2004 May;121(5):709-17 [15151211.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):736-47 [15166665.001]
  • [Cites] Am J Surg Pathol. 2004 Jun;28(6):748-55 [15166666.001]
  • [Cites] J Neurooncol. 2004 May;68(1):19-23 [15174517.001]
  • [Cites] J Invest Dermatol. 2004 Jun;122(6):1495-502 [15175042.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] J Invest Dermatol. 2004 Jul;123(1):213-9 [15191563.001]
  • [Cites] Br J Dermatol. 2004 Jun;150(6):1202-7 [15214912.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):946-53 [15105813.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):954-61 [15133473.001]
  • [Cites] Nat Rev Cancer. 2004 Aug;4(8):644-53 [15286744.001]
  • [Cites] Leukemia. 2004 Oct;18(10):1722-6 [15356642.001]
  • [Cites] Am J Clin Pathol. 2004 Oct;122(4):582-7 [15487457.001]
  • [Cites] J Clin Oncol. 1991 Apr;9(4):539-47 [1648596.001]
  • [Cites] Lancet. 1991 Nov 9;338(8776):1175-6 [1682595.001]
  • [Cites] Cancer. 1993 Mar 15;71(6):2097-104 [8382999.001]
  • [Cites] J Clin Oncol. 1993 May;11(5):937-42 [8387578.001]
  • [Cites] Am J Surg Pathol. 1993 Sep;17(9):859-68 [8394652.001]
  • [Cites] Ultrastruct Pathol. 1993 May-Aug;17(3-4):455-8 [7505507.001]
  • [Cites] Am J Pathol. 1988 Dec;133(3):446-50 [2849300.001]
  • [Cites] Blood. 1989 Oct;74(5):1678-89 [2477085.001]
  • [Cites] Blood. 1989 Oct;74(5):1796-800 [2506953.001]
  • [Cites] Hum Pathol. 1990 Jun;21(6):624-9 [1693592.001]
  • [Cites] Am J Surg Pathol. 1990 Nov;14(11):1047-60 [2173429.001]
  • [Cites] Am J Pathol. 1991 Jun;138(6):1413-22 [1711289.001]
  • [Cites] J Invest Dermatol. 1994 Feb;102(2):231-5 [8106752.001]
  • [Cites] Ann Hematol. 1995 Feb;70(2):103-5 [7880923.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1343-54 [7751878.001]
  • [Cites] Blood. 1996 Apr 15;87(8):3437-41 [8605362.001]
  • [Cites] Histopathology. 1996 Jan;28(1):25-32 [8838117.001]
  • [Cites] Am J Clin Pathol. 1996 Oct;106(4):498-503 [8853039.001]
  • [Cites] Arch Dermatol. 1996 Nov;132(11):1304-8 [8915307.001]
  • [Cites] Histopathology. 1996 Nov;29(5):455-9 [8951491.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):439-49 [9053841.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1394-404 [9028963.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] J Clin Pathol. 1996 Sep;49(9):762-3 [9038763.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] N Engl J Med. 1997 May 8;336(19):1391-2 [9139227.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):135-8 [9149743.001]
  • [Cites] Hum Pathol. 1997 Jul;28(7):757-9 [9224740.001]
  • [Cites] Hum Pathol. 1997 Jul;28(7):850-61 [9224756.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] Arch Esp Urol. 1997 Oct;50(8):906-8 [9463289.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2080-5 [9626207.001]
  • [Cites] Am J Clin Pathol. 1998 Sep;110(3):327-33 [9728607.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):779-81 [9739446.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1192-202 [9777981.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1):111-6 [9894461.001]
  • [Cites] Am J Clin Pathol. 1999 Apr;111(4):488-94 [10191768.001]
  • [Cites] Cancer. 1999 Apr 1;85(7):1626-35 [10193956.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Am J Clin Pathol. 1999 Aug;112(2):263-70 [10439808.001]
  • [Cites] Mod Pathol. 1999 Sep;12(9):903-6 [10496599.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1673-9 [15520070.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):720-3 [15536159.001]
  • [Cites] Mod Pathol. 2005 Feb;18(2):235-43 [15475930.001]
  • [Cites] Histopathology. 2005 Mar;46(3):241-55 [15720410.001]
  • [Cites] Blood. 2005 May 1;105(9):3671-8 [15308563.001]
  • [Cites] Leukemia. 2005 Apr;19(4):652-8 [15703784.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Clin Cancer Res. 2005 May 1;11(9):3349-52 [15867234.001]
  • [Cites] Leukemia. 2004 Jan;18(1):146-55 [14603341.001]
  • [Cites] N Engl J Med. 2004 Jan 15;350(3):239-48 [14724303.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Feb;26(2):104-7 [14767197.001]
  • [Cites] Histopathology. 2004 Mar;44(3):268-76 [14987231.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):408-16 [15023046.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 21;96(8):586-94 [15100336.001]
  • [Cites] Blood. 2004 May 15;103(10):3662-8 [14726400.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3343-8 [15256428.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3358-60 [15297316.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7179-81 [15534090.001]
  • [Cites] J Clin Pathol. 2004 Dec;57(12):1258-63 [15563664.001]
  • [Cites] J Pathol. 2005 Jan;205(1):92-101 [15586381.001]
  • [Cites] Am J Surg Pathol. 2005 Jan;29(1):69-82 [15613857.001]
  • [Cites] J Pathol. 2005 Jan;205(2):255-74 [15643667.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1315-26 [3141260.001]
  • [Cites] Blood. 2000 Jul 15;96(2):398-404 [10887098.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Histopathology. 2000 Jul;37(1):10-8 [10931213.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1257-65 [10976700.001]
  • [Cites] Leukemia. 2000 Sep;14(9):1533-59 [10994999.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1143-9 [11048810.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1401-16 [15489644.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1979 Aug 23;383(3):293-317 [158873.001]
  • [Cites] Am J Med. 1983 Feb;74(2):228-31 [6824003.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] Histopathology. 1985 Jan;9(1):81-97 [3884481.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • [Cites] Blood. 2000 Nov 1;96(9):2993-3000 [11049976.001]
  • [Cites] Arch Pathol Lab Med. 2000 Dec;124(12):1804-8 [11100061.001]
  • [Cites] J Clin Lab Anal. 2000;14(6):299-304 [11138613.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):699-706 [11159207.001]
  • [Cites] Br J Haematol. 2001 Mar;112(4):909-15 [11298585.001]
  • [Cites] Br J Haematol. 2001 May;113(2):275-95 [11380391.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):875-83 [11420458.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1209-16 [11493472.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3602-10 [11504742.001]
  • [Cites] Mod Pathol. 2001 Nov;14(11):1093-9 [11706069.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jan;87(1):105-11 [11788631.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):216-24 [11812943.001]
  • [Cites] Am J Hematol. 2002 Feb;69(2):127-31 [11835349.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):724-32 [12023576.001]
  • [Cites] Am J Surg Pathol. 2002 Jun;26(6):733-41 [12023577.001]
  • [Cites] J Invest Dermatol. 2002 Jun;118(6):941-8 [12060387.001]
  • [Cites] J Clin Pathol. 2002 Sep;55(9):684-8 [12194999.001]
  • [Cites] Am J Clin Pathol. 2002 Nov;118(5):773-9 [12428799.001]
  • [Cites] Mod Pathol. 2002 Nov;15(11):1221-6 [12429802.001]
  • [Cites] Surv Ophthalmol. 2002 Sep-Oct;47(5):470-90 [12431695.001]
  • [Cites] Virchows Arch. 2002 Dec;441(6):614-7 [12461620.001]
  • [Cites] Am J Surg Pathol. 2003 Jan;27(1):16-26 [12502924.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):319-24 [12527929.001]
  • [Cites] Int J Surg Pathol. 2001 Oct;9(4):287-93 [12574844.001]
  • [Cites] Am J Clin Pathol. 2003 Feb;119(2):205-12 [12579990.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):293-302 [12604885.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e115-8 [12653596.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):487-93 [12657933.001]
  • [Cites] Am J Surg Pathol. 2003 Apr;27(4):522-31 [12657939.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):241-9 [12688340.001]
  • [Cites] Mod Pathol. 2003 May;16(5):424-9 [12748248.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] Am J Clin Pathol. 2003 Oct;120(4):617-25 [14560573.001]
  • [Cites] Am J Surg Pathol. 2003 Nov;27(11):1473-6 [14576483.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1513-22 [14657710.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1538-45 [14657713.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1183-91 [14674895.001]
  • (PMID = 16623775.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 145
  • [Other-IDs] NLM/ PMC1448691
  •  go-up   go-down


83. Gabriel Grzona E, Buxhoeveden R, Chirife AM, Marino L, Bugari G: [Primary gastric CD30 (Ki-1)-positive anaplastic large cell lymphoma]. Cir Esp; 2010 Oct;88(4):263-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary gastric CD30 (Ki-1)-positive anaplastic large cell lymphoma].
  • [Transliterated title] Linfoma gástrico primario anaplásico de células grandes CD30 (Ki-1) positivo.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Antigens, CD30 / analysis. Female. Humans. Middle Aged


84. Yanagi T, Shimizu T, Kodama K, Nemoto-Hasebe I, Kasai M, Shimizu H: CD30-positive primary cutaneous anaplastic large-cell lymphoma and definite squamous cell carcinoma. Clin Exp Dermatol; 2009 Oct;34(7):e293-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30-positive primary cutaneous anaplastic large-cell lymphoma and definite squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Lymphoma, Primary Cutaneous Anaplastic Large Cell / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology


85. Nowak J, Friend AL: Loblolly pine and slash pine responses to acute aluminum and acid exposures. Tree Physiol; 2006 Sep;26(9):1207-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each species was exposed to a single soil application of aluminum chloride (0.33 M AlCl(3), pH 2.5), hydrochloric acid (0.39 M HCl, pH 0.6) or water, with or without mycorrhizal inoculation with Pisolithus tinctorius (Coker and Couch).
  • After 20 weeks without inoculation, survival in AlCl(3) and HCl treatments averaged 52% for loblolly pine and 72% for slash pine.
  • Inoculation also resulted in improved survival and growth of individual families in AlCl(3), but not in HCl treatments.

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • Hazardous Substances Data Bank. HYDROGEN CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740496.001).
  • [ISSN] 0829-318X
  • [Journal-full-title] Tree physiology
  • [ISO-abbreviation] Tree Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Chlorides; 0 / Soil; 3CYT62D3GA / aluminum chloride; QTT17582CB / Hydrochloric Acid
  •  go-up   go-down


86. Bittencourt AL, Barbosa HS, Vieira MD, Farré L: Adult T-cell leukemia/lymphoma (ATL) presenting in the skin: clinical, histological and immunohistochemical features of 52 cases. Acta Oncol; 2009;48(4):598-604
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma (ATL) presenting in the skin: clinical, histological and immunohistochemical features of 52 cases.
  • BACKGROUND: Adult T-cell leukemia/lymphoma (ATL) is a severe disease caused by HTLV-I.
  • Immunohistochemistry was performed using CD3, CD4, CD5, CD7, CD8, CD20, CD25, CD30 and CD45RO markers.
  • Ki-67 was used to evaluate the proliferative index.
  • Patterns resembling mycosis fungoides (MF) were found in 19 cases and anaplastic large-cell lymphoma (ALCL) in two cases.
  • Primary cutaneous ATL had a longer MST (48 months) than the secondary cutaneous ATL (7 months) and the difference was statistically significant, but no statistically significant difference was found between the MST of CD8-positive and negative cases.
  • The smoldering type presented a longer survival (58 months) and histological aspects suggestive of better prognosis in contrast to the PCT type that had a shorter survival (20 months) and histological characteristics suggestive of worse outcome.
  • [MeSH-major] Antigens, CD8 / analysis. CD8-Positive T-Lymphocytes / virology. Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / mortality. Skin Neoplasms / diagnosis. Skin Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD / analysis. Cell Proliferation. Child. Female. Humans. Immunohistochemistry. Immunophenotyping. Ki-67 Antigen / analysis. Male. Middle Aged. Survival Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19165640.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD8; 0 / Ki-67 Antigen
  •  go-up   go-down


87. Zhang W, McQueen T, Schober W, Rassidakis G, Andreeff M, Konopleva M: Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation. Leukemia; 2005 Nov;19(11):1977-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation.
  • Anaplastic large-cell lymphoma (ALCL) is a heterogeneous lymphoma category in which a subset of cases carry the t(2;5)(p23;q35) or variant translocations resulting in overexpression of anaplastic lymphoma kinase (ALK).
  • In this study, we investigated the potential therapeutic effects and mechanisms of action of LY293111 in ALCL cell lines.
  • LY293111 inhibited proliferation of both ALK(+) and ALK(-) ALCL cell in a dose-dependent fashion and induced complete G(1)-S cell cycle arrest, which was accompanied by upregulation of p27 and downregulation of cyclin E.
  • Pretreatment with LY293111 for 4 h resulted in profound inhibition of serum-induced phosphorylation of extracellular-regulated kinases-1 and 2 and Akt and a concomitant increase in the phosphorylation of the stress-activated kinase c-jun N-terminal kinases (JNK).
  • The phospho-JNK inhibitor SP600125 partially protected Sup-M2 cells from LY293111-induced apoptosis, PARP cleavage and ROS generation, suggesting a role for JNK in LY293111-induced cell death.
  • These results warrant further studies of LY293111 in ALCL.
  • [MeSH-major] Apoptosis / drug effects. Benzoates / pharmacology. Cell Cycle / drug effects. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Cell Cycle Proteins / biosynthesis. Cyclin E / biosynthesis. Cyclin-Dependent Kinase Inhibitor p27. Dose-Response Relationship, Drug. Down-Regulation. Humans. JNK Mitogen-Activated Protein Kinases / metabolism. MAP Kinase Kinase 4. Membrane Potentials. Mitochondria / physiology. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphorylation. Reactive Oxygen Species. Receptors, Leukotriene B4. Tumor Cells, Cultured. Tumor Suppressor Proteins / biosynthesis. Up-Regulation

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16151469.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / P01 CA55164
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzoates; 0 / Cell Cycle Proteins; 0 / Cyclin E; 0 / LY 293111; 0 / Reactive Oxygen Species; 0 / Receptors, Leukotriene B4; 0 / Tumor Suppressor Proteins; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 2.7.11.24 / JNK Mitogen-Activated Protein Kinases; EC 2.7.12.2 / MAP Kinase Kinase 4; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  •  go-up   go-down


88. Sung CO, Ko YH, Park S, Kim K, Kim W: Immunoreactivity of CD99 in non-Hodgkin's lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma. J Korean Med Sci; 2005 Dec;20(6):952-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoreactivity of CD99 in non-Hodgkin's lymphoma: unexpected frequent expression in ALK-positive anaplastic large cell lymphoma.
  • To verify the spectrum of CD99-expressing lymphoid malignancy, an immunohistochemical study for CD99 was carried out in 182 cases of non-Hodgkin's lymphoma, including 21 lymphoblastic lymphomas, 11 small lymphocytic lymphomas, 9 mantle cell lymphomas, 12 follicular lymphomas, 37 diffuse large B cell lymphomas, 18 Burkitt's lymphomas, 28 NK/T-cell lymphomas, 8 angioimmunoblastic T-cell lymphomas, 23 peripheral T-cell lymphomas, unspecified, and 15 systemic anaplastic large cell lymphomas.
  • CD99 was positive in all T-lymphoblastic lymphomas and in 60% of B-lymphoblastic lymphomas.
  • Majority of T and NK cell lymphomas were negative for CD99, except anaplastic large cell lymphomas (ALCLs).
  • Eight of 15 cases (54%) of ALCLs reacted with anti CD99 antibody.
  • Seven of 10 (70%) ALK positive ALCLs expressed CD99, whereas only 1 of 5 (20%) ALK negative ALCLs were positive.
  • Of the mature B-cell lymphomas, 5.4% (2/37) of diffuse large B cell lymphomas and 11.1% (2/18) of Burkitt's lymphomas expressed CD99.
  • In conclusion, CD99 is infrequently expressed in mature B and T cell lymphomas, except ALK-positive ALCL.
  • High expression of CD99 in ALK-positive ALCL is unexpected finding and its biologic and clinical significances have yet to be clarified.
  • [MeSH-major] Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. Lymphoma, Large B-Cell, Diffuse / immunology. Lymphoma, Non-Hodgkin / immunology. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 1991 Feb;2 Suppl 2:33-8 [1646624.001]
  • [Cites] Am J Pathol. 1990 Nov;137(5):1047-57 [2173409.001]
  • [Cites] Histopathology. 1993 Dec;23(6):557-61 [8314240.001]
  • [Cites] Hum Pathol. 1994 Apr;25(4):396-9 [8163272.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] Blood. 1996 May 15;87(10):4340-7 [8639794.001]
  • [Cites] Hum Pathol. 1996 Dec;27(12):1273-6 [8958297.001]
  • [Cites] Mod Pathol. 1997 Apr;10(4):277-82 [9110287.001]
  • [Cites] J Immunol. 1997 Sep 1;159(5):2250-8 [9278313.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):769-73 [9720506.001]
  • [Cites] J Immunol. 1998 Nov 1;161(9):4671-8 [9794396.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):690-5 [10354133.001]
  • [Cites] J Korean Med Sci. 2005 Feb;20(1):50-5 [15716602.001]
  • [Cites] Mod Pathol. 2000 Apr;13(4):452-8 [10786814.001]
  • [Cites] Virchows Arch. 2000 Sep;437(3):270-4 [11037347.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):527-35 [11485911.001]
  • [Cites] Leuk Lymphoma. 2001 Aug;42(4):587-94 [11697486.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4540-6 [12036886.001]
  • [Cites] J Korean Med Sci. 2002 Aug;17(4):483-9 [12172043.001]
  • [Cites] FEBS Lett. 2003 Nov 20;554(3):478-84 [14623115.001]
  • [Cites] Cancer Cell. 2004 Apr;5(4):353-64 [15093542.001]
  • [Cites] Oncogene. 2004 Jul 22;23(33):5664-74 [15184883.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6127-31 [2844401.001]
  • [Cites] Blood. 1994 Jan 15;83(2):415-25 [7506950.001]
  • (PMID = 16361803.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ PMC2779325
  •  go-up   go-down


89. Yang SL, Song H, Tang YM: [Primary anaplastic large cell lymphoma originated from lung in a case]. Zhonghua Er Ke Za Zhi; 2007 Dec;45(12):949
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary anaplastic large cell lymphoma originated from lung in a case].
  • [MeSH-major] Lung Neoplasms / congenital. Lymphoma, Large-Cell, Anaplastic / physiopathology


90. Rudzki Z, Rucińska M, Jurczak W, Skotnicki AB, Maramorosz-Kurianowicz M, Mruk A, Piróg K, Utych G, Bodzioch P, Srebro-Stariczyk M, Włodarska I, Stachura J: ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review. Pol J Pathol; 2005;56(1):37-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
  • Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare, recently defined tumor distinct in many aspects from ALK-positive anaplastic large cell lymphoma (ALCL).
  • We present two additional cases of ALK+DLBCL recently diagnosed in our department and a review of literature.
  • A 48-year old man presented with a large upper neck mass growing slowly over 18 months.
  • Histologically the tumor was diagnosed as an ALK-positive diffuse large B-cell lymphoma. with plasmablastic features.
  • Large, frequently intrasinusoidal tumor cells expressed CD138, EMA, weakly IgA and kappa, but were negative for other B-cell markers, T-cell markers and CD30.
  • At the diagnosis the patient manifested with the stage IIIB.
  • The patient died of massive bleeding from his decomposing tumor 3 months after the diagnosis.
  • A 49-year old man complaining of abdominal pain revealed abdominal lymphadenomegaly and a gastric infiltrate, involving the deep portions of the gastric wall.
  • The tumor showed immunoblastic/anaplastic morphology, with some Reed-Sternberg-like cells positive for ALK.
  • The tumor demonstrated similar "null" B/T phenotype with positivity for IgA, lambda, EMA and LCA.
  • ALK-positive DLBCL affects mostly middle-aged men, shows generally poor but stage-dependent prognosis (at least 60% mortality rate), presents typically as a lymph node-based disseminated disease, and very rarely involves the bone marrow.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921012.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 17
  •  go-up   go-down


91. Krenova Z, Sterba J, Blatny J, Kren L, Slany J: A case of anaplastic large cell lymphoma-induced hemophagocytic lymphohistiocytosis in an adolescent female. Pediatr Blood Cancer; 2007 Dec;49(7):1056
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of anaplastic large cell lymphoma-induced hemophagocytic lymphohistiocytosis in an adolescent female.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis


92. Isogai R, Fukao M, Kawada A: Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy. J Dermatol; 2007 Aug;34(8):556-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment for recurrence of primary cutaneous anaplastic large-cell lymphoma in elderly patient with etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) therapy.
  • Primary cutaneous anaplastic large cell lymphoma (C-ALCL) is a malignant lymphoma with a relatively good prognosis, consisting of CD30-positive, undifferentiated, large cells.
  • We report an elderly patient with C-ALCL which recurred after cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) therapy, but was effectively treated with the third-generation etoposide, mitoxantrone, cyclophosphamide, vincristine, prednisolone and bleomycin (VNCOP-B) regimen.
  • It is characterized by the completion of treatment in 8 weeks, its applicability on an outpatient basis, and a low incidence of cardiotoxicity and mucosal symptoms.
  • In conclusion, the VNCOP-B regimen might be an effective treatment for elderly patients with good performance status, CHOP-resistant patients or patients with aggressive non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large-Cell, Anaplastic / drug therapy. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / drug therapy


93. Wang Y, Gao BY, Xu XM, Xu WY, Xu GY: Characterization of floc size, strength and structure in various aluminum coagulants treatment. J Colloid Interface Sci; 2009 Apr 15;332(2):354-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Different Al coagulants--conventional Al salt (AlCl(3)), polyaluminum chloride (PAC-1) and the purified polyaluminum chloride (PAC-2)--were investigated for the coagulation of humic acid (HA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19185875.001).
  • [ISSN] 1095-7103
  • [Journal-full-title] Journal of colloid and interface science
  • [ISO-abbreviation] J Colloid Interface Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Mosunjac MB, Sundstrom JB, Mosunjac MI: Unusual presentation of anaplastic large cell lymphoma with clinical course mimicking fever of unknown origin and sepsis: autopsy study of five cases. Croat Med J; 2008 Oct;49(5):660-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual presentation of anaplastic large cell lymphoma with clinical course mimicking fever of unknown origin and sepsis: autopsy study of five cases.
  • AIM: To describe a subset of cases with the unusual clinical and histomorphological presentation of anaplastic large cell lymphoma (ALCL) mimicking fever of unknown origin (FUO) and sepsis.
  • METHODS: A pathology database was searched using full term Systematized Nomenclature of Medicine codes for ALCL to identify 23ALCL cases from the period 1999-2006.
  • Of those, five cases that did not have a correct premortem diagnosis were further analyzed to elucidate the reasons for delayed and incorrect pre-mortem diagnosis.
  • The analyzed data included clinical presentation, duration of symptoms, duration of hospital stay, premortem presumed cause of death, white blood cell count, platelet count, anion gap and blood pH, liver enzymes (alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase, alkaline phosphatase), lactate, coagulation tests (prothrombin time, partial thromboplastin time, fibrinogen, D-dimers), microbiology cultures, and radiology and surgical pathology reports.
  • Autopsy reports were reviewed for description of major gross findings, initial clinical diagnosis, and cause of death.
  • RESULTS: Five fatal and pre-mortem unrecognized ALCL cases were characterized by rapid decline, with histologic findings showing predominantly extranodal involvement, intravascular lymphomatosis, and hemophagocytosis.
  • CONCLUSIONS: There is a distinct group of ALCLs with unique and specific clinical, gross autopsy, and histopathologic findings.
  • Recognition of this clinical variant may facilitate early detection and potentially timely diagnosis and therapy.
  • [MeSH-major] Fever of Unknown Origin / etiology. Lymphoma, Large-Cell, Anaplastic / complications. Lymphoma, Large-Cell, Anaplastic / diagnosis. Sepsis / etiology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Sepsis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2000 Apr;142(4):766-70 [10792229.001]
  • [Cites] Int J Hematol. 1997 Apr;65(3):215-26 [9114593.001]
  • [Cites] Dig Dis Sci. 2000 Nov;45(11):2240-6 [11215747.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):219-28 [11266530.001]
  • [Cites] Eur J Dermatol. 2001 May-Jun;11(3):203-8 [11358725.001]
  • [Cites] Cancer. 2001 Nov 1;92(9):2237-46 [11745277.001]
  • [Cites] Haematologica. 2002 Feb;87(2):ELT05 [11836182.001]
  • [Cites] Br J Dermatol. 2002 Jun;146(6):1091-5 [12072086.001]
  • [Cites] Ann Oncol. 2002 Nov;13(11):1827-32 [12419758.001]
  • [Cites] Leuk Lymphoma. 2003 Feb;44(2):353-5 [12688357.001]
  • [Cites] Pol Merkur Lekarski. 2003 Feb;14(80):133-5 [12728673.001]
  • [Cites] Nephrol Dial Transplant. 2003 Jun;18(6):1214-6 [12748358.001]
  • [Cites] Clin Lab Haematol. 2003 Jun;25(3):185-6 [12755796.001]
  • [Cites] Beijing Da Xue Xue Bao. 2003 Apr 18;35(2):143-5 [12920829.001]
  • [Cites] Am J Clin Pathol. 2003 Oct;120(4):617-25 [14560573.001]
  • [Cites] Leuk Lymphoma. 2004 Oct;45(10):2001-6 [15370244.001]
  • [Cites] Cancer. 1981 Aug 1;48(3):779-82 [7248904.001]
  • [Cites] J Histochem Cytochem. 1982 Jul;30(7):713-6 [6286753.001]
  • [Cites] Hematol Oncol. 1989 Nov-Dec;7(6):441-9 [2553576.001]
  • [Cites] Arch Pathol Lab Med. 1991 Feb;115(2):188-92 [1847037.001]
  • [Cites] Am J Hematol. 1991 Jun;37(2):112-9 [1648880.001]
  • [Cites] Med Pediatr Oncol. 1993;21(9):665-9; discussion 669-70 [8413001.001]
  • [Cites] Med Klin (Munich). 1994 Jun 15;89(6):299-304 [8072452.001]
  • [Cites] J Dermatol. 1995 Oct;22(10):743-6 [8586753.001]
  • [Cites] Metabolism. 1997 Mar;46(3):306-21 [9054475.001]
  • [Cites] Am J Hematol. 1997 Mar;54(3):219-24 [9067501.001]
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):115-7 [9448189.001]
  • [Cites] Histopathology. 1997 Dec;31(6):555-62 [9447388.001]
  • [Cites] Hum Pathol. 1999 Aug;30(8):978-81 [10452512.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3355-7 [15205267.001]
  • [Cites] Leuk Lymphoma. 2005 Mar;46(3):461-3 [15621840.001]
  • [Cites] Int Urol Nephrol. 2004;36(3):393-6 [15783113.001]
  • [Cites] Hum Pathol. 2005 May;36(5):494-504 [15948116.001]
  • [Cites] Diagn Cytopathol. 2005 Aug;33(2):106-9 [16007654.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):806-11 [16084951.001]
  • [Cites] World J Gastroenterol. 2005 Oct 21;11(39):6221-4 [16273656.001]
  • [Cites] Virchows Arch. 2005 Dec;447(6):1000-6 [16189700.001]
  • [Cites] Histopathology. 2006 Apr;48(5):481-504 [16623775.001]
  • [Cites] Nat Clin Pract Neurol. 2007 Jan;3(1):24-35 [17205072.001]
  • [Cites] Am J Clin Pathol. 2007 Mar;127(3):458-64 [17276937.001]
  • [Cites] J Ky Med Assoc. 2000 Apr;98(4):161-5 [10816985.001]
  • (PMID = 18925700.001).
  • [ISSN] 1332-8166
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  • [Other-IDs] NLM/ PMC2582359
  •  go-up   go-down


95. Lee HW, Kim K, Kim W, Ko YH: ALK-positive diffuse large B-cell lymphoma: report of three cases. Hematol Oncol; 2008 Jun;26(2):108-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: report of three cases.
  • Diffuse large B-cell lymphoma positive for anaplastic lymphoma kinase (ALK(+) DLBCL) is a rare variant of diffuse large B-cell lymphoma, with characteristic morphological, immunohistochemical and cytogenetic features.
  • Only 34 cases of ALK-positive diffuse large B-cell lymphoma have so far been reported in the literature.
  • We examined three new cases, which showed similar characteristics to previously reported cases, but with peculiar nuclear-membrane staining for ALK protein in one patient and a 5'-ALK gene deletion in another.
  • All of them had stage IV disease at initial presentation, with poor outcomes.
  • The tumour cells showed immunoblastic/plasmablastic histology and were positive for ALK and Oct2, but negative for CD3, CD20, CD79a, CD30 and PAX5.
  • These three cases suggest that different types of cytogenetic aberrations may involve the ALK gene in ALK-positive diffuse large B-cell lymphoma leading to peculiar immunohistochemical staining patterns.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / therapy. Protein-Tyrosine Kinases / biosynthesis. Protein-Tyrosine Kinases / genetics
  • [MeSH-minor] Adult. Cell Nucleus / metabolism. Chromosome Aberrations. Cytogenetics. Female. Gene Deletion. Humans. Immunohistochemistry. Immunophenotyping. In Situ Hybridization, Fluorescence. Male. Receptor Protein-Tyrosine Kinases. Treatment Outcome

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18220322.001).
  • [ISSN] 0278-0232
  • [Journal-full-title] Hematological oncology
  • [ISO-abbreviation] Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


96. Rianthavorn P, Cain JP, Turman MA: Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH. Pediatr Nephrol; 2008 Aug;23(8):1367-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH.
  • We report a case of a 13-year-old boy with extensively metastasized anaplastic large-cell lymphoma.
  • Conivaptan played a significant role in this situation by allowing provision of a large amount of intravenous fluid prior to and during induction chemotherapy.
  • [MeSH-major] Benzazepines / administration & dosage. Hyponatremia / drug therapy. Inappropriate ADH Syndrome / drug therapy. Lymphoma, Large B-Cell, Diffuse / complications. Tumor Lysis Syndrome / prevention & control

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Drug Rev. 2007 Fall;25(3):261-79 [17919259.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Nov;35(11):1495-9 [12824060.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2003 Dec;17(4):471-503 [14687585.001]
  • [Cites] Postgrad Med J. 2006 Mar;82(965):216-9 [16517805.001]
  • [Cites] Ann Intern Med. 1985 Feb;102(2):164-8 [3966753.001]
  • [Cites] Am J Health Syst Pharm. 2007 Jul 1;64(13):1385-95 [17592003.001]
  • [Cites] J Intensive Care Med. 2003 Jan-Feb;18(1):3-8 [15189662.001]
  • [Cites] Am J Nephrol. 2007;27(5):447-57 [17664863.001]
  • [Cites] Am J Nephrol. 2005 May-Jun;25(3):240-9 [15914973.001]
  • (PMID = 18437428.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzazepines; 0NJ98Y462X / conivaptan
  •  go-up   go-down


97. van Houdt IS, Muris JJ, Hesselink AT, Kramer D, Cillessen SA, Moesbergen LM, Vos W, Hooijberg E, Meijer CJ, Kummer JA, Oudejans JJ: Expression of c-FLIP is primarily detected in diffuse large B-cell lymphoma and Hodgkin's lymphoma and correlates with lack of caspase 8 activation. Histopathology; 2007 Dec;51(6):778-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of c-FLIP is primarily detected in diffuse large B-cell lymphoma and Hodgkin's lymphoma and correlates with lack of caspase 8 activation.
  • AIMS: Inhibition of apoptosis is important in the pathogenesis of lymphomas. c-FLIP, a regulator of caspase 8-mediated apoptosis, plays an important role in protecting normal B and T cells from apoptosis and possibly also in lymphomas.
  • Because of contradictory reports about immunohistochemical detection of c-FLIP expression, the aim was to test the specificity of four antibodies in c-FLIP-transfected cells and subsequently to investigate expression of c-FLIP in different types of lymphoma.
  • In primary lymphomas c-FLIP expression was restricted to Hodgkin's lymphomas (> 90%) and diffuse large B-cell lymphomas (44%).
  • Burkitt lymphomas and indolent B-cell lymphomas were negative in all cases.
  • No expression was detected in primary T-cell lymphomas, although expression was observed in one relapsed ALK+ anaplastic large cell lymphoma.
  • CONCLUSIONS: c-FLIP is important in escape of B cells from apoptosis during normal follicle centre cell reaction and may thus be an important early event in the development of B-cell-derived lymphomas.
  • [MeSH-major] CASP8 and FADD-Like Apoptosis Regulating Protein / biosynthesis. Caspase 8 / metabolism. Hodgkin Disease / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18042067.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CASP8 and FADD-Like Apoptosis Regulating Protein; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


98. zur Nieden NI, Baumgartner L: Assessing developmental osteotoxicity of chlorides in the embryonic stem cell test. Reprod Toxicol; 2010 Sep;30(2):277-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing developmental osteotoxicity of chlorides in the embryonic stem cell test.
  • This study employs the embryonic stem cell test to unambiguously characterize the effect of four chlorides with increasing valence, NaCl, LiCl, MgCl(2) and AlCl(3), utilizing the capacity of murine embryonic stem cells to differentiate into bone forming cells in vitro.
  • Although this effect was clearer for AlCl(3) than for the other tested chlorides, we suggest extreme caution should still be given when administering any chloride during pregnancy.
  • [MeSH-minor] Animal Testing Alternatives / methods. Animals. Cell Differentiation / drug effects. Cell Line. Cell Survival / drug effects. Dose-Response Relationship, Drug. Mice. Osteogenesis / drug effects. Osteogenesis / physiology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published by Elsevier Inc.
  • (PMID = 20447454.001).
  • [ISSN] 1873-1708
  • [Journal-full-title] Reproductive toxicology (Elmsford, N.Y.)
  • [ISO-abbreviation] Reprod. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chlorides; 0 / Teratogens
  •  go-up   go-down


99. Detrait M, Poirier L, Roy DC, Kiss T, Busque L, Cohen S, Lachance S, Sauvageau G, Roy J: Diphyllobothriasis, a rare cause of profuse diarrhea following autologous transplantation. Bone Marrow Transplant; 2009 Jul;44(2):131-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Diarrhea / parasitology. Diphyllobothriasis / parasitology. Hematopoietic Stem Cell Transplantation. Lymphoma, Large-Cell, Anaplastic / therapy

  • Genetic Alliance. consumer health - Diarrhea.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Diarrhea.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169286.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 6490C9U457 / Praziquantel
  •  go-up   go-down


100. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G: The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer; 2008 Jan;8(1):11-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The anaplastic lymphoma kinase in the pathogenesis of cancer.
  • However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas.
  • The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many molecular mechanisms.
  • [MeSH-major] Lymphoma / enzymology. Lymphoma / genetics. Protein-Tyrosine Kinases / genetics. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Humans. Lymphoma, Large B-Cell, Diffuse / enzymology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, T-Cell / enzymology. Lymphoma, T-Cell / genetics. Receptor Protein-Tyrosine Kinases / metabolism. Translocation, Genetic






Advertisement